var title_f17_30_17888="Fracture of thumb metacarpal base Bennetts";
var content_f17_30_17888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fracture of thumb metacarpal base: Type I (Bennett's)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each of these anteroposterior radiographs shows an intra-articular fracture of the thumb metacarpal. The Type I or \"Bennett's\" fracture of the proximal 1st metacarpal illustrated here is characterized by its articular involvement and the persistent attachment of the volar fragment to the trapezium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17888=[""].join("\n");
var outline_f17_30_17888=null;
var title_f17_30_17889="Perineal group A streptococcal disease";
var content_f17_30_17889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Perineal group A streptococcal disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the fiery or beefy red appearance of the infected skin which is a clinical hallmark of group A streptococcal perineal disease.",
"    <br>",
"     (A) Perivaginal infection.",
"     <br>",
"      (B) Perianal infection.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17889=[""].join("\n");
var outline_f17_30_17889=null;
var title_f17_30_17890="Hemophagocytic syndrome";
var content_f17_30_17890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infection-associated hemophagocytic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow from a child with hemophagocytic syndrome, secondary to Epstein-Barr virus infection. Reactive histiocytes show phagocytosis of nucleated red blood cells (red arrows) and platelets (black arrows). Wright-Giemsa stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17890=[""].join("\n");
var outline_f17_30_17890=null;
var title_f17_30_17891="Doppler LA appendage flow during normal sinus rhythm";
var content_f17_30_17891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler interrogation of LA appendage flow during normal sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 528px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A diagram of left atrial appendage (LAA) flow in sinus rhythm. is shown on panel A; panel B shows the pulsed-Doppler tracing of LAA flow. Phases of LAA flow include LAA contraction (1); LAA filing (2); systolic reflection waves (positive and negative) (3); early diastolic LAA outflow (4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 1999, 34:1867-77.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17891=[""].join("\n");
var outline_f17_30_17891=null;
var title_f17_30_17892="Ground glass nodule";
var content_f17_30_17892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ground-glass solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ground-glass solitary pulmonary nodule in the right middle lobe (arrow), most likely representing a focus of atypical alveolar hyperplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17892=[""].join("\n");
var outline_f17_30_17892=null;
var title_f17_30_17893="RML and RLL atelectasis II";
var content_f17_30_17893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reversal of right middle and lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upright chest radiograph from the previous patient with right middle and lower lobe atelectasis taken the next day after chest physiotherapy. The right middle and lower lobes are now partially aerated and the right heart border and the right hemidiaphragm are faintly visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17893=[""].join("\n");
var outline_f17_30_17893=null;
var title_f17_30_17894="Sacrococcygeal germ cell tumors";
var content_f17_30_17894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sacrococcygeal germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Rachel A Egler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17894/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17894/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/30/17894/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ cell tumors (GCTs) that arise outside the testes or the ovaries are classified as extragonadal. Extragonadal GCTs typically arise in midline locations, and specific sites vary with age. In adults, the most common sites are the anterior mediastinum, retroperitoneum, and the pineal and suprasellar regions. In infants and young children, sacrococcygeal teratomas (SCTs) are most common.",
"   </p>",
"   <p>",
"    SCTs are discussed here. Extragonadal GCTs arising in the central nervous system, and in the mediastinum and retroperitoneum are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"     \"Pediatric intracranial germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCT is the most common GCT of childhood. In the pediatric population, SCTs account for 40 percent of all GCTs and for up to 78 percent of all extragonadal GCTs. Rarely, sacrococcygeal teratomas may present in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCT is the most frequently recognized fetal neoplasm, with an estimated incidence of about 1 in 27,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/3\">",
"     3",
"    </a>",
"    ]. SCT are more common in females than males, with a 3 to 4:1 ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. SCTs with malignant elements generally are not seen in infants. The incidence of malignant elements within SCTs increases with age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratomas often are comprised of cells that represent all three germ cell layers. They have solid, cystic or mixed components. Unlike teratomas in other locations, SCTs often do not have a capsule or pseudocapsule, which contributes to the difficulty in achieving a complete resection.",
"   </p>",
"   <p>",
"    GCTs can include mature, immature, and malignant tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mature teratomas &mdash; Mature teratomas consist of fully differentiated tissues from various somatic sites. These tissues may be small islands of cells mixed together, or they can include fully functional glandular structures such as pancreatic Langerhans cells or sebaceous glands. Fully developed bone, hair, and teeth have been found in mature teratomas.",
"     </li>",
"     <li>",
"      Immature teratomas &mdash; Immature teratomas include at least a small fraction of cells that are comprised of embryonal components or incompletely differentiated tissue structures. Primitive neuroectodermal features, such as primitive neural tubes and immature rosettes, are common. The Gonzalez-Crussi grading system has been used to describe the amount of immature tissue within the tumor: Grade 0 - mature teratoma only, Grade 1 - &lt;10 percent immature tissue, Grade 2 - 10 to 50 percent immature tissue and Grade 3 - &gt;50 percent immature tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/6\">",
"       6",
"      </a>",
"      ]. Other grading systems have also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malignant teratomas &mdash; SCTs that contain any malignant elements are considered malignant. Between 11 and 35 percent of SCTs are malignant, and many of these will have elevated tumor markers [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4,10,11\">",
"       4,10,11",
"      </a>",
"      ]. The most common malignant element is a yolk sac component, which produces alpha fetoprotein (AFP) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4,9,12\">",
"       4,9,12",
"      </a>",
"      ]. Other malignant elements can include embryonal carcinoma and primitive neuroectodermal tumor (PNET).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Microfoci of malignant elements can be missed on pathologic sectioning. Therefore, screening with AFP and beta human chorionic gonadotropin (beta-hCG) is part of the initial evaluation of patients with SCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consistent genetic changes have been identified in mature and immature teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, both gonadal and extragonadal GCTs of infancy frequently have gain of chromosomes 1q and 20q, as well as loss of chromosomes 1p and 6q. In contrast, postpubertal malignant GCTs are associated with the isochromosome 12p abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCT is generally a tumor of infancy that may be asymptomatic or present with signs of obstruction of the rectum or bladder. A small number of children present with weakness, pain, or paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/15\">",
"     15",
"    </a>",
"    ]. The Altman Classification describes the extent to which a tumor is external and or internal (",
"    <a class=\"graphic graphic_figure graphicRef81430 \" href=\"UTD.htm?43/47/44788\">",
"     figure 1",
"    </a>",
"    ). Type 1 tumors are primarily external, while type 4 lesions are completely internal. Type 1 and 2 tumors are the most obvious on clinical exam. In the UK Children's Cancer Study Group (CCSG) experience with 37 SCTs, Altman types 1, 2, 3, and 4 were present in 62, 14, 19, and 6 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 4 tumors typically are found later in infancy and early childhood, compared to tumors with an external component (types 1, 2, and 3). Type 4 SCTs can present with",
"    <span class=\"nowrap\">",
"     obstipation/constipation,",
"    </span>",
"    abdominal pain, or a palpable mass. Malignant elements are more frequent in type 4 SCTs, with an incidence of 38 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the increasing use of prenatal ultrasound, many SCTs are now identified in utero. SCTs arising in utero can cause polyhydramnios, fetal distress, congestive heart failure leading to hydrops fetalis due to intratumoral hemorrhage, and preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the first evaluation is discovery of the tumor by prenatal ultrasound. Although prenatal MRI is possible, CT or MRI of the primary site is most commonly done to assess the extent of internal tumor after birth. Staging should include a CT of the chest and bone scan.",
"   </p>",
"   <p>",
"    Serum levels of AFP and beta-hCG should be assessed at diagnosis to look for the presence of malignant components in the tumor. Because these tumors generally present at birth or early in infancy, interpretation of an elevated AFP can be difficult and must consider the age of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/17\">",
"     17",
"    </a>",
"    ]. AFP levels often decline slowly to reach normal levels in the very young, but a continued decline should be present [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Benign SCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of SCTs do not contain malignant elements. Early, complete surgical resection is the cornerstone of management for mature and immature SCTs in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/2,8,9,12,16,19,20\">",
"     2,8,9,12,16,19,20",
"    </a>",
"    ]. In some cases, resection may be undertaken in utero. Surgical resection is often an extensive procedure and can cause significant acute and long term side effects. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgical considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Incomplete resections are associated with a significantly higher rate of recurrence. In a German series, recurrence was more frequent after incomplete resection (49 versus 11 percent, in those with complete resection) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/12\">",
"     12",
"    </a>",
"    ]. Similarly, the Children's Cancer Group (CCG) observed a recurrence rate of 11 percent in patients with mature SCT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4\">",
"     4",
"    </a>",
"    ]. Of these, two recurrences were mature teratoma, while the remaining seven had yolk sac tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both German and UK investigators found no benefit for adjuvant chemotherapy in patients with immature teratoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Similarly, the American Intergroup study demonstrated that observation after complete resection was an effective strategy in patients with immature teratoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Malignant SCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with malignant SCT following surgery, platinum-based chemotherapy is a critical component of treatment. As in adults with advanced GCTs, the most widely used combinations are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (BEJ). These regimens are effective therapy both at diagnosis for patients with malignant SCTs and for those who recur with malignant elements after resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stage I and II malignant SCTs treated with complete surgical resection and chemotherapy have an overall survival (OS) at five years that exceeds 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/10,21,22\">",
"     10,21,22",
"    </a>",
"    ]. Metastatic tumors have a lower event-free survival (EFS) and OS. In a combined analysis of three German trials that utilized surgery followed by a five-drug chemotherapy regimen, outcomes were worse for those with metastatic tumors (five-year EFS 67 versus 83 percent in those without metastases, and OS 69 versus 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To facilitate surgical resection and to improve outcomes in patients with advanced disease with a malignant component, chemotherapy has been used to treat patients with advanced disease prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/12,21,23\">",
"     12,21,23",
"    </a>",
"    ]. In patients with locally advanced or metastatic disease, those who received neoadjuvant chemotherapy followed by resection had an EFS of 79 percent with an OS of 83 percent at five years, while those who had an immediate attempt at complete resection had both EFS and OS of 49 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/12\">",
"     12",
"    </a>",
"    ]. The American Intergroup data showed similar results, with all non-thoracic, extragonadal GCTs having an EFS and OS of 82 and 87 percent, respectively, at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/23\">",
"     23",
"    </a>",
"    ]. In the UK CCSG experience, patients with malignant sacrococcygeal GCT who were treated with neoadjuvant chemotherapy with BEJ had an EFS of 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for patients with completely resected (stage I) SCT with malignant components is controversial. These patients are generally eligible for studies that include chemotherapy; however, they have also been observed without chemotherapy in some cases. As an example, in the CCG experience, six patients with yolk sac tumor components did not receive immediate chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4\">",
"     4",
"    </a>",
"    ]. Of these, two recurred and were successfully treated with chemotherapy at recurrence, with long term survival of more than nine years. Another four patients with nonmetastatic malignant SCT did receive adjuvant chemotherapy, and all survived at least five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, in the German experience, three patients with stage I malignant SCTs less than 5 cm were managed without chemotherapy with no recurrences at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/12\">",
"     12",
"    </a>",
"    ]. Conversely, the CCG immature teratoma data included two fully resected SCT patients with microfoci of malignant elements, who both relapsed during observation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of patients described in these studies is too small to make definitive recommendations regarding observation only for patients with malignant SCT. In the current Children's Oncology Group trial, patients with a completely resected malignant SCT are considered intermediate risk and receive at least three cycles of BEP therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for complete excision of an SCT often is quite extensive. It must include removal of the coccyx to be considered complete. Other considerations include early ligation of the sacral vessels and sterile circumferential preparation of the body due to the potential need for intraoperative change in approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/25\">",
"     25",
"    </a>",
"    ]. If a complete resection cannot be achieved in the first surgery, a second procedure may be required to complete the resection, particularly for tumors with malignant elements [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/10,23\">",
"     10,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite successful control of the tumor in the majority of patients, functional sequelae are common and can impair quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The frequency of serious complications was assessed in a series of 79 patients from the Netherlands who were treated over a 23-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/26\">",
"     26",
"    </a>",
"    ]. Bowel dysfunction (soiling, including total fecal incontinence in some cases) was reported in 13 percent and urinary incontinence was observed in 31 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both mature and immature teratomas can recur locally and at distant sites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. As an example, relapses were observed in 10 percent of patients with mature and 18 percent of immature tumors in a German series of extracranial nontesticular teratomas diagnosed between 1982 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/12\">",
"     12",
"    </a>",
"    ]. Malignant elements (most commonly yolk sac tumor) were present in 52 percent of cases. All tumors with distant relapse also had recurrent locoregional disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with recurrent disease are treated with further surgery or chemotherapy depending upon the pathology and extent of the recurrent tumor. SCT patients who recur with malignant elements can often be salvaged with platinum-based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/8,9,12\">",
"     8,9,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Malignant SCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients previously treated with chemotherapy (BEP or JEB) for malignant disease can be treated with a number of salvage regimens for recurrent malignant GCT including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/28\">",
"     28",
"    </a>",
"    ];",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , ifosfamide and platinum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/29\">",
"     29",
"    </a>",
"    ]; and high dose chemotherapy with stem cell rescue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17894/abstract/27,30-32\">",
"     27,30-32",
"    </a>",
"    ]. The current Children's Oncology Group uses a combination of paclitaxel, ifosfamide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sacrococcygeal teratoma (SCT) is the most common extragonadal germ cell tumor (GCT) in infancy and early childhood. SCTs are generally benign tumors. However, malignant elements can be present, and their frequency increases with the age of the patient. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mature and immature SCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mature and immature teratomas without malignant elements, we recommend complete surgical resection (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). There does not appear to be a role for adjuvant chemotherapy following surgery. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Benign SCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Malignant SCTs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with SCTs that contain malignant elements, we recommend surgical resection, when this can be accomplished without excessive surgical morbidity, followed by adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest adjuvant chemotherapy with a platinum-based regimen such as BEP or BEJ, rather than alternative chemotherapeutic regimens (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Malignant SCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who undergo a complete resection for an SCT with malignant elements, observation, rather than adjuvant chemotherapy, may be an alternative, although there has been limited prospective evaluation of this approach. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Malignant SCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with locally advanced or metastatic malignant SCTs, we recommend neoadjuvant chemotherapy prior to resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Malignant SCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are treated with either adjuvant or neoadjuvant chemotherapy, we suggest a platinum-based regimen, rather than alternative chemotherapeutic regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Malignant SCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/1\">",
"      Audet IM, Goldhahn RT Jr, Dent TL. Adult sacrococcygeal teratomas. Am Surg 2000; 66:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/2\">",
"      Ng EW, Porcu P, Loehrer PJ Sr. Sacrococcygeal teratoma in adults: case reports and a review of the literature. Cancer 1999; 86:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/3\">",
"      Swamy R, Embleton N, Hale J. Sacrococcygeal teratoma over two decades: birth prevalence, prenatal diagnosis and clinical outcomes. Prenat Diagn 2008; 28:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/4\">",
"      Rescorla FJ, Sawin RS, Coran AG, et al. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 1998; 33:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/5\">",
"      Schropp KP, Lobe TE, Rao B, et al. Sacrococcygeal teratoma: the experience of four decades. J Pediatr Surg 1992; 27:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/6\">",
"      Harms D, Zahn S, G&ouml;bel U, Schneider DT. Pathology and molecular biology of teratomas in childhood and adolescence. Klin Padiatr 2006; 218:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/7\">",
"      Huddart SN, Mann JR, Robinson K, et al. Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I. Neonatal. Pediatr Surg Int 2003; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/8\">",
"      Mann JR, Gray ES, Thornton C, et al. Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience. J Clin Oncol 2008; 26:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/9\">",
"      Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 1999; 17:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/10\">",
"      Calaminus G, Schneider DT, B&ouml;kkerink JP, et al. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89. J Clin Oncol 2003; 21:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/11\">",
"      Wakhlu A, Misra S, Tandon RK, Wakhlu AK. Sacrococcygeal teratoma. Pediatr Surg Int 2002; 18:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/12\">",
"      G&ouml;bel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol 2001; 19:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/13\">",
"      Hu J, Schuster AE, Fritsch MK, et al. Deletion mapping of 6q21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis. Oncogene 2001; 20:8042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/14\">",
"      Veltman I, Veltman J, Janssen I, et al. Identification of recurrent chromosomal aberrations in germ cell tumors of neonates and infants using genomewide array-based comparative genomic hybridization. Genes Chromosomes Cancer 2005; 43:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/15\">",
"      Mahour GH. Sacrococcygeal teratomas. CA Cancer J Clin 1988; 38:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/16\">",
"      Altman RP, Randolph JG, Lilly JR. Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973. J Pediatr Surg 1974; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/17\">",
"      Wu JT, Book L, Sudar K. Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 1981; 15:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/18\">",
"      Barreto MW, Silva LV, Barini R, et al. Alpha-fetoprotein following neonatal resection of sacrococcygeal teratoma. Pediatr Hematol Oncol 2006; 23:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/19\">",
"      Derikx JP, De Backer A, van de Schoot L, et al. Factors associated with recurrence and metastasis in sacrococcygeal teratoma. Br J Surg 2006; 93:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/20\">",
"      Gabra HO, Jesudason EC, McDowell HP, et al. Sacrococcygeal teratoma--a 25-year experience in a UK regional center. J Pediatr Surg 2006; 41:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/21\">",
"      Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18:3809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/22\">",
"      Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004; 22:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/23\">",
"      Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006; 24:2544.",
"     </a>",
"    </li>",
"    <li>",
"     Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors. (Protocol summary available on line: file://www.clinicaltrials.gov/ct2/show/NCT00053352?term=agct0132&amp;rank=1, accessed on April 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/25\">",
"      Ein SH, Mancer K, Adeyemi SD. Malignant sacrococcygeal teratoma--endodermal sinus, yolk sac tumor--in infants and children: a 32-year review. J Pediatr Surg 1985; 20:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/26\">",
"      Derikx JP, De Backer A, van de Schoot L, et al. Long-term functional sequelae of sacrococcygeal teratoma: a national study in The Netherlands. J Pediatr Surg 2007; 42:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/27\">",
"      Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/28\">",
"      Kondagunta GV, Motzer RJ. Chemotherapy for advanced germ cell tumors. J Clin Oncol 2006; 24:5493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/29\">",
"      Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/30\">",
"      Tada T, Takizawa T, Nakazato F, et al. Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue. J Neurooncol 1999; 44:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/31\">",
"      Margolin KA, Doroshow JH, Frankel P, et al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biol Blood Marrow Transplant 2005; 11:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17894/abstract/32\">",
"      Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357:340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5200 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17894=[""].join("\n");
var outline_f17_30_17894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Benign SCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Malignant SCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgical considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mature and immature SCTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Malignant SCTs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5200|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/47/44788\" title=\"figure 1\">",
"      Class Sacro CTs AAP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=related_link\">",
"      Pediatric intracranial germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_30_17895="Female pelvic bones ligaments";
var content_f17_30_17895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Female pelvic bones and ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17895=[""].join("\n");
var outline_f17_30_17895=null;
var title_f17_30_17896="Management of children and adolescents with fragile X syndrome";
var content_f17_30_17896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of children and adolescents with fragile X syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Hilde Van Esch, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17896/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/30/17896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children and adolescents with fragile X syndrome (also called fragile X mental retardation syndrome, X-linked mental retardation and macroorchidism, and Martin-Bell syndrome) will be discussed here. The clinical features, diagnosis, and prenatal screening are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=see_link\">",
"     \"Prenatal screening and diagnosis for fragile X syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children and adolescents with fragile X syndrome (FXS) is individualized according to the child's cognitive and behavioral symptoms, strengths, and weaknesses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\", section on 'Additional evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interventions may include individualized education plans, speech and language therapy, occupational therapy, behavior therapy, and pharmacotherapy. Few controlled trials have been performed to assess the effectiveness of these interventions in children with FXS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, they are effective in children with other cognitive or behavioral problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37306?source=see_link\">",
"     \"Specific learning disabilities in children: Educational management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families of individuals with fragile X syndrome (FXS) should be referred to a geneticist or genetic counselor for a detailed discussion of the inheritance of the fragile X mental retardation-1 (FMR1) mutation and testing of other family members [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. FXS test results should be interpreted for the family according to the guidelines established by the National Society of Genetic Counselors and the American Society of Human Genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Family members at risk for premutation or full mutation of FMR1 should receive information about possible emotional, neurologic, and reproductive problems [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DEVELOPMENTAL AND EDUCATIONAL INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with fragile X syndrome (FXS) usually have special educational needs and should be referred for early developmental stimulation and educational programs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Most children with FXS have difficulties with mathematics and expressive language skills and relative strengths in receptive language skills [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/10\">",
"     10",
"    </a>",
"    ]. However, developmental strengths and weaknesses must be assessed on an individual basis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9\">",
"     9",
"    </a>",
"    ]. Children with FXS and autism require additional educational interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BEHAVIORAL INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions may be effective in promoting coping skills and reducing problematic behaviors (eg, aggression, stereotypic behaviors, self-injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. There are few empirical studies of the effectiveness of behavioral interventions for children and adolescents with fragile X syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment strategies are guided by the therapist's experience and understanding of factors associated with problematic behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. Problematic behaviors often are precipitated and reinforced by social",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental events (eg, anxiety, sensory overload, change in routine, the amount of attention the child is receiving, etc.) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9,14-17\">",
"     9,14-17",
"    </a>",
"    ]. Environmental changes (eg, small class size, avoiding excessive stimulation, avoiding sudden changes) may reduce the frequency of problem behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Individuals with fragile X syndrome can be taught to recognize stressful situations and use self-calming techniques before responding inappropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral interventions for children with intellectual disability are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=see_link&amp;anchor=H5#H5\">",
"     \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\", section on 'Behavior intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children and adolescents with fragile X syndrome who have higher levels of function may benefit from counseling or psychotherapy to focus on anxiety reduction, socialization, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13,19\">",
"     13,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HEALTH SUPERVISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with fragile X syndrome (FXS) should receive routine health supervision and prompt referral for medical, therapeutic, educational, and consultative services (eg, early intervention services, speech therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/8,9,20\">",
"     8,9,20",
"    </a>",
"    ]. Health supervision guidelines from the American Academy of Pediatrics Committee on Genetics are available online (",
"    <a class=\"external\" href=\"file://pediatrics.aappublications.org/content/127/5/994/T2.expansion.html\">",
"     file://pediatrics.aappublications.org/content/127/5/994/T2.expansion.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families with fragile X mutation or premutation benefit from parental and social supports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9\">",
"     9",
"    </a>",
"    ]. Personal and family support should be reviewed at regularly scheduled health supervision visits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/8\">",
"     8",
"    </a>",
"    ]. Internet-based information and support resources are provided below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to intellectual disability and language and behavior problems, children and adolescents with fragile X syndrome (FXS) are at risk for a number of medical problems, listed below. Surveillance for these problems and appropriate intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral should occur at regularly scheduled health maintenance visits throughout childhood, adolescence, and young adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated medical concerns in children and adolescents with fragile X syndrome include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/8,14,21\">",
"     8,14,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flat feet (80 percent) and other connective tissue manifestations (eg, ligamentous laxity, inguinal hernia) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/21,22\">",
"       21,22",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23190?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and management of foot pain in the young athlete\", section on 'Flexible pes planus'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gastroesophageal reflux (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"       \"Gastroesophageal reflux in infants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mitral valve prolapse (typically develops during adolescence or adulthood; present in 50 to 80 percent of adults) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/21\">",
"       21",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link\">",
"       \"Definition and diagnosis of mitral valve prolapse\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recurrent otitis media (60 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/21,23\">",
"       21,23",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"       \"Acute otitis media in children: Diagnosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Refractive errors (20 percent), strabismus (8 to 30 percent), and nystagmus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/21\">",
"       21",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"       \"Refractive errors in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Seizures (as many as 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. The peak incidence is between six months and four years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13,25,26\">",
"       13,25,26",
"      </a>",
"      ]. The possibility of seizures should be considered in older children and adolescents if school performance is declining. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"       \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scoliosis (&lt;20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/14\">",
"       14",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=see_link\">",
"       \"Overview of treatment for adolescent depression\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anticipatory guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics guidelines for health supervision of children with fragile X syndrome suggest providing anticipatory guidance according to the following schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth to 1 month &mdash; Infants in this age group generally are identified through prenatal testing because of a positive family history. Review support groups and available services. Discuss how and what to tell family members and friends [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      1 month to 1 year &mdash; Discuss irritability and tantrums. Refer for early intervention services (in the United States).",
"     </li>",
"     <li>",
"      1 to 5 years &mdash; Review the preschool program. Refer for speech and language therapy, physical therapy, and occupational therapy as indicated. Formal developmental evaluation may be warranted.",
"     </li>",
"     <li>",
"      5 to 13 years &mdash; Assess effectiveness of behavioral interventions. Discuss how parents and siblings address behavioral problems. Review development and appropriateness of school placement (eg, visual presentation of information, small classroom size, individualized attention, speech and language therapy, occupational therapy). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Developmental and educational interventions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Behavioral interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      13 to 21 years &mdash; Review behavioral concerns (eg, violent outbursts). Assess psychosocial development, physical and sexual development, and fertility in boys and girls. Discuss the need for and level of supervision, and discuss the need for birth control. The National Fragile X Foundation (",
"      <a class=\"external\" href=\"file://www.fragilex.org/\">",
"       www.fragilex.org",
"      </a>",
"      ) provides resources for discussing sexuality with children and adolescents with FXS. Discuss the need for vocational training and group home placement if appropriate. Facilitate transition to adult medical care as appropriate or desired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychopharmacologic therapy may be necessary for children and adolescents with fragile X (FXS) syndrome and attention deficit hyperactivity disorder, anxiety, mood instability, or maladaptive behaviors (eg, perseveration, aggression, self-injury) that significantly affect social interaction and are not controlled with environmental or behavioral interventions. There is no specific therapy for enhancing cognitive abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychopharmacologic intervention is individualized according to symptoms; it must be closely monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/1\">",
"     1",
"    </a>",
"    ]. Specific agents may help with some problematic behaviors but exacerbate others [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few controlled studies evaluating the use of psychopharmacologic interventions in children and adolescents with FXS. Evidence to support their use is derived from observational surveys of clinical populations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperactivity and inattention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inattention and hyperactivity in children with FXS are typically treated with stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"     4",
"    </a>",
"    ]. Observational studies suggest that stimulants are beneficial in approximately 70 percent of boys with FXS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4,27\">",
"     4,27",
"    </a>",
"    ]. In a small placebo-controlled crossover trial,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    in addition to behavioral interventions and individualized therapy was associated with improved teacher ratings of socialization skills and attention span [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefits of stimulants may include increased attention span and decreased distractibility, motor activity, fidgeting, and impulsivity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"     4",
"    </a>",
"    ]. Adverse effects of stimulants may include appetite suppression, insomnia, moodiness, increased aggressiveness or irritability, and aggravation of anxiety or perseveration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children younger than five years, stimulants may exacerbate irritability or other behavior problems. Nonstimulant therapies (eg, alpha-2 agonists such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    ) often are used in this age group to treat hyperactivity, inattention, and hyperarousal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. In observational studies, alpha-2 agonists are beneficial in approximately 60 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4,28,29\">",
"     4,28,29",
"    </a>",
"    ]. Adverse effects of alpha-2 agonists include decreased blood pressure and sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=see_link\">",
"     Minocycline",
"    </a>",
"    (a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    analogue) and metabotropic glutamate receptor antagonists are under evaluation in randomized trials in patients with FXS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety, compulsive, perseverative behaviors, and mood symptoms may be managed with antidepressants, such as selective serotonin reuptake inhibitors (SSRIs). Observational studies suggest that treatment with SSRIs relieves anxiety in approximately 50 percent of patients with FXS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. However, approximately 20 percent of treated patients reported activation (restlessness, mood change, disinhibited behavior, aggression) with SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefits of SSRIs may include decreased fixations and compulsive behaviors, decreased irritability, easier transitions, increased comfort in social situations, and ability to tolerate environmental stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"     4",
"    </a>",
"    ]. Adverse effects may include activation, changes in appetite, insomnia, nausea, and suicidal ideation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link&amp;anchor=H18#H18\">",
"     \"Psychopharmacological treatment for adolescent depression\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irritability, aggression, mood instability, and perseverative behaviors may respond to treatment with antipsychotic agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/35/7737?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. In controlled trials in children with autism, risperidone has been shown to be beneficial in controlling aggressive and aberrant behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Aripiprazole also may target distractibility, anxiety, mood instability, and aberrant social behaviors.",
"   </p>",
"   <p>",
"    Benefits of antipsychotics may include improved sleep and decreased anxiety, agitation, perseveration, and aggression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"     4",
"    </a>",
"    ]. Adverse effects may include sedation, nausea, constipation, dystonic and extrapyramidal reactions, gynecomastia, and weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures in children with FXS generally are controlled with a single anticonvulsant (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/46/16104?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"     zonisamide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticonvulsants with adverse effects that include hypotonia, clumsiness, cognitive dulling, and daytime sedation should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/4,13\">",
"     4,13",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    is usually avoided because it is associated with gingival hypertrophy, and it is difficult to manage dental problems in children with FXS because of their hypersensitivity.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    may exacerbate behavior problems and also should be avoided in children with FXS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of investigational therapies target biochemical pathways that are thought to play a role in the clinical manifestations of fragile X syndrome (FXS). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabotropic glutamate receptor 5 (mGluR5) antagonists &mdash; Excessive mGluR5 signaling is thought to contribute to some of the behavioral abnormalities and cognitive deficits of FXS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/3,13,37\">",
"       3,13,37",
"      </a>",
"      ]. In animal models, mGluR5 antagonists have demonstrated improvements in behavior and cognition; reduction of anxiety, depression, and seizures; and correction of underlying abnormal cellular processes such as aberrant cell signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/3,38-40\">",
"       3,38-40",
"      </a>",
"      ]. Trials in humans are ongoing. (See",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"       clinicaltrials.gov",
"      </a>",
"      for information about clinical studies).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"       Lithium",
"      </a>",
"      &mdash; Lithium downregulates the phospholipase C signaling pathway, which is used by mGluR5 and other receptors to activate dendritic translation and has the potential to correct excessive dendritic protein synthesis in FXS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13\">",
"       13",
"      </a>",
"      ]. A small open-labeled trial of lithium in 15 males with FXS (6 to 23 years) found significant improvement in behavioral functioning, adaptive behavior, and verbal memory [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ampakines (positive AMPA receptor modulators) &mdash; Excessive mGluR activity contributes to reduced synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and excessive internalization of AMPA receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/13\">",
"       13",
"      </a>",
"      ]. Reduced AMPA receptor signaling is another potential target for therapy. In a controlled trial, treatment with CX516 (an ampakine) had no effect on cognitive function in a cohort of subjects with FXS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PRADER-WILLI PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of children with the Prader-Willi phenotype of FXS is similar to that for children with Prader-Willi syndrome without FXS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Evaluation and management of comorbidities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Growth hormone treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Management of feeding and obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life expectancy for individuals with fragile X syndrome is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/9\">",
"     9",
"    </a>",
"    ]. Adult males typically have an intelligence quotient (IQ) in the moderate intellectual disability range (the average IQ in adult males with a completely methylated full mutation is approximately 40) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/3,43\">",
"     3,43",
"    </a>",
"    ]. However, IQ may vary from mild to severe. Males with incomplete methylation of FMR1 may have IQ in the borderline or low normal range. Adult females with the full mutation usually have IQ in the normal or mild intellectual disability range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internet-based resources for healthcare providers, patients, and families of with fragile X syndrome include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17896/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Fragile X Foundation (",
"      <a class=\"external\" href=\"file://www.fragilex.org/\">",
"       www.fragilex.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      FRAXA Research Foundation Inc (",
"      <a class=\"external\" href=\"file://www.fraxa.org/\">",
"       www.fraxa.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The National Institute of Child Health and Human Development (",
"      <a class=\"external\" href=\"file://www.nichd.nih.gov/health/topics/fragile_x_syndrome.cfm\">",
"       www.nichd.nih.gov/health/topics/fragile_x_syndrome.cfm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      GeneTests (",
"      <a class=\"external\" href=\"file://www.genetests.org/\">",
"       www.genetests.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/4/12355?source=see_link\">",
"       \"Patient information: Fragile X syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of children and adolescents with fragile X syndrome (FXS) is individualized according to the child's cognitive and behavioral symptoms, strengths, and weaknesses. Interventions may include individualized education plans, speech and language therapy, occupational therapy, behavior therapy, and pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Families of individuals with FXS should be referred to a geneticist or genetic counselor for a detailed discussion of the inheritance of the fragile X mental retardation-1 (FMR1) mutation and testing of other family members. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with FXS usually have special educational needs and should be referred for early developmental stimulation and educational programs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Developmental and educational interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavioral interventions may be effective in promoting coping skills and reducing problematic behaviors (eg, aggression, stereotypic behaviors, self-injury). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Behavioral interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health supervision of children with FXS involves surveillance for a number of associated medical problems, including flat feet, hyperextensible joints, inguinal hernia, gastroesophageal reflux, mitral valve prolapse, recurrent otitis media, refractive errors, strabismus, nystagmus, seizures, scoliosis, depression, and anxiety. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychopharmacologic intervention is individualized according to symptoms (eg, inattention, hyperactivity, anxiety, mood instability) and must be closely monitored. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Saul RA, Tarleton JC. FMR1-related disorders. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex (Accessed on December 31, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/2\">",
"      Hersh JH, Saul RA, Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics 2011; 127:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/3\">",
"      Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet 2008; 16:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/4\">",
"      Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev 2004; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/5\">",
"      McConkie-Rosell A, Abrams L, Finucane B, et al. Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns 2007; 16:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/6\">",
"      McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/7\">",
"      Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/8\">",
"      Health supervision for children with fragile X syndrome. American Academy of Pediatrics Committee on Genetics. Pediatrics 1996; 98:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/9\">",
"      Visootsak J, Warren ST, Anido A, Graham JM Jr. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila) 2005; 44:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/10\">",
"      Roberts JE, Mirrett P, Burchinal M. Receptive and expressive communication development of young males with fragile X syndrome. Am J Ment Retard 2001; 106:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/11\">",
"      Weiskop S, Richdale A, Matthews J. Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurol 2005; 47:94.",
"     </a>",
"    </li>",
"    <li>",
"     Hills-Epstein J, Riley K, Sobesky W. The treatment of emotional and behavioral problems. In: Fragile X syndrome: Diagnosis, treatment, and research, 3rd ed, Hagerman RJ, Hagerman PJ (Eds), Johns Hopkins University Press, Baltimore 2002. p.339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/13\">",
"      Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/14\">",
"      Reiss AL, Hall SS. Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 2007; 16:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/15\">",
"      Durand VM, Carr EG. Social influences on \"self-stimulatory\" behavior: analysis and treatment application. J Appl Behav Anal 1987; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/16\">",
"      Iwata BA, Pace GM, Dorsey MF, et al. The functions of self-injurious behavior: an experimental-epidemiological analysis. J Appl Behav Anal 1994; 27:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/17\">",
"      Hanley GP, Iwata BA, McCord BE. Functional analysis of problem behavior: a review. J Appl Behav Anal 2003; 36:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/18\">",
"      Restivo L, Ferrari F, Passino E, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A 2005; 102:11557.",
"     </a>",
"    </li>",
"    <li>",
"     Braden ML. Education. In: Children with fragile X syndrome: A parent's guide, Woodbine House, Bethesda 2000. p.243.",
"    </li>",
"    <li>",
"     Wilson GN, Cooley WC. The fragile X syndrome. In: Preventive management of children with congenital anomalies and syndromes, Cambridge University Press, Cambridge, United Kingdom 2000. p.175.",
"    </li>",
"    <li>",
"     Hagerman R. Fragile X syndrome. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.218.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/22\">",
"      Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am 1990; 72:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/23\">",
"      Hagerman RJ, Altshul-Stark D, McBogg P. Recurrent otitis media in the fragile X syndrome. Am J Dis Child 1987; 141:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/24\">",
"      Hagerman PJ, Stafstrom CE. Origins of epilepsy in fragile X syndrome. Epilepsy Curr 2009; 9:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/25\">",
"      Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol 2002; 44:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/26\">",
"      Musumeci SA, Hagerman RJ, Ferri R, et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999; 40:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/27\">",
"      Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 1988; 30:377.",
"     </a>",
"    </li>",
"    <li>",
"     Erickson CA, Stigler KA, Posey DJ, MCDougle CJ. Managing maladaptive behaviors in fragile X patients. J Fam Practice (on-line) 2006 www.jfponline.com/Pages.asp?AID=4443 (Accessed on December 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/29\">",
"      Hagerman RJ, Riddle JE, Roberts LS, et al. Survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct 1995; 8:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/30\">",
"      Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009; 46:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/31\">",
"      Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010; 115:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/32\">",
"      Hagerman RJ, Fulton MJ, Leaman A, et al. A survey of fluoxetine therapy in fragile X syndrome. Dev Brain Dysfunct 1994; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/33\">",
"      McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/34\">",
"      Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/35\">",
"      Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/36\">",
"      Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/37\">",
"      Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/38\">",
"      Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000; 295:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/39\">",
"      Tatarczyska E, Klodziska A, Chojnacka-W&oacute;jcik E, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001; 132:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/40\">",
"      Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012; 74:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/41\">",
"      Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008; 29:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/42\">",
"      Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006; 16:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17896/abstract/43\">",
"      Merenstein SA, Sobesky WE, Taylor AK, et al. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996; 64:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2925 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17896=[""].join("\n");
var outline_f17_30_17896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DEVELOPMENTAL AND EDUCATIONAL INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BEHAVIORAL INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HEALTH SUPERVISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperactivity and inattention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other behaviors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PRADER-WILLI PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23190?source=related_link\">",
"      Clinical features and management of foot pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=related_link\">",
"      Overview of treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/4/12355?source=related_link\">",
"      Patient information: Fragile X syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23399?source=related_link\">",
"      Prenatal screening and diagnosis for fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37306?source=related_link\">",
"      Specific learning disabilities in children: Educational management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_30_17897="HELLP syndrome";
var content_f17_30_17897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HELLP syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Baha M Sibai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17897/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/30/17897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP syndrome refers to a syndrome characterized by hemolysis with a microangiopathic blood smear, elevated liver enzymes, and a low platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/1\">",
"     1",
"    </a>",
"    ]. The syndrome probably represents a severe form of preeclampsia (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ), but this relationship remains controversial. As many as 15 to 20 percent of affected patients do not have antecedent hypertension or proteinuria, leading some experts to believe that HELLP is a separate disorder from preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Both severe preeclampsia and HELLP syndrome may be associated with other hepatic manifestations, including infarction, hemorrhage, and rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND ONSET OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP develops in approximately 1 to 2 per 1000 pregnancies overall and in 10 to 20 percent of women with severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia.",
"    </span>",
"    The majority of cases are diagnosed between 28 and 36 weeks of gestation.",
"   </p>",
"   <p>",
"    An illustrative series included 437 women who had 442 pregnancies complicated by the HELLP syndrome; 70 percent occurred prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"     5",
"    </a>",
"    ]. Of these patients, approximately 80 percent were diagnosed prior to 37 weeks of gestation and fewer than 3 percent developed the disease between 17 and 20 weeks of gestation. The disease presented postpartum in 30 percent, usually within 48 hours of delivery, but occasionally as long as seven days after birth. Only 20 percent of postpartum patients with HELLP had evidence of preeclampsia antepartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of HELLP is varied (",
"    <a class=\"graphic graphic_table graphicRef64665 \" href=\"UTD.htm?7/6/7275\">",
"     table 3",
"    </a>",
"    ). Symptoms typically develop in the third trimester, but, as discussed above, second trimester or postpartum disease is also possible. The most common clinical presentation is abdominal pain and tenderness in the midepigastrium, right upper quadrant, or below the sternum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients also have nausea, vomiting, and malaise, which may be mistaken for a nonspecific viral illness or viral hepatitis, particularly if the serum aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) are markedly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/6\">",
"     6",
"    </a>",
"    ]. Hypertension (blood pressure",
"    <span class=\"nowrap\">",
"     &ge;140/90)",
"    </span>",
"    and proteinuria are present in approximately 85 percent of cases, but it is important to remember that either or both may be absent in women with otherwise severe HELLP syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious maternal morbidity may be present at initial presentation or develop shortly thereafter. This includes disseminated intravascular coagulation (DIC), abruptio placentae, acute renal failure, pulmonary edema, subcapsular liver hematoma, and retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"     5",
"    </a>",
"    ]. Jaundice and ascites may also be present. Bleeding related to thrombocytopenia is an uncommon presentation. Some patients are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HELLP syndrome is based upon the presence of the laboratory abnormalities comprising its name in women with a diagnosis of preeclampsia. Laboratory work-up includes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with platelet count",
"     </li>",
"     <li>",
"      Peripheral smear",
"     </li>",
"     <li>",
"      AST, bilirubin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest obtaining these laboratory tests in all pregnant women with gestational hypertension, preeclampsia, or proteinuria with symptoms of preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the degree of laboratory abnormality diagnostic of HELLP syndrome. Some studies use AST",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    ALT) and LDH values above the upper limit of normal, while others require elevations of at least two standard deviations above the mean [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/8\">",
"     8",
"    </a>",
"    ]. Due to differences in assays used to measure these enzymes, an elevated value in one hospital may be near normal in another.",
"   </p>",
"   <p>",
"    HELLP syndrome and severe preeclampsia are probably part of a disease spectrum. A precise definition of HELLP is necessary for research purposes and for predicting maternal complications. We require the presence of all of the following criteria to diagnose HELLP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia with characteristic schistocytes (also called helmet cells) on blood smear (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      ). Other signs suggestive of hemolysis include an elevated indirect bilirubin and a low serum haptoglobin concentration (&le;25",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count &le;100,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Total bilirubin &ge;1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Serum AST &ge;70",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"      Some investigators obtain ALT levels instead of, or in addition to, AST levels. An advantage of the AST is that it is a single test that reflects both hepatocellular necrosis and red cell hemolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who do not meet all of the above laboratory abnormalities are considered to have partial HELLP syndrome. These patients may progress to complete expression of HELLP syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging tests, particularly computed tomography (CT) or magnetic resonance (MR) imaging, are useful when complications such as hepatic infarction, hematoma, or rupture are suspected (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one series of 33 women with HELLP and complaints of severe right upper quadrant abdominal pain associated with either shoulder pain, neck pain, or relapsing hypotension, imaging the liver revealed abnormal findings in 15 (45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/9\">",
"     9",
"    </a>",
"    ]. The most common abnormalities were subcapsular hematoma and intraparenchymal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP syndrome may occasionally be confused with other diseases complicating pregnancy: acute fatty liver of pregnancy, gastroenteritis, hepatitis, appendicitis, gallbladder disease, idiopathic thrombocytopenic purpura, lupus flare, antiphospholipid syndrome, hemolytic-uremic syndrome, or thrombotic thrombocytopenic purpura (",
"    <a class=\"graphic graphic_table graphicRef53332 \" href=\"UTD.htm?31/31/32252\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ]. (See individual topic reviews on these subjects).",
"   </p>",
"   <p>",
"    In one series of 46 women who developed liver disease during pregnancy severe enough to require admission to a liver failure unit, 70 percent had acute fatty liver and 15 percent had HELLP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of the remaining patients had liver disease that was unrelated to pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute fatty liver of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP may be difficult to distinguish clinically from acute fatty liver of pregnancy since both occur at the same time in gestation and share several clinical features (",
"    <a class=\"graphic graphic_figure graphicRef57913 \" href=\"UTD.htm?12/14/12514\">",
"     figure 1",
"    </a>",
"    ), but it is important to differentiate between the two disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional laboratory testing can be helpful. Prolongation of the prothrombin (PT) and activated partial thromboplastin time (aPTT), low glucose concentration, and elevated creatinine concentration are more common in women with acute fatty liver than those with HELLP.",
"   </p>",
"   <p>",
"    Of note, women with acute fatty liver are more likely than women with HELLP to have offspring with an inherited defect in mitochondrial beta-oxidation of fatty acids, such as long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, short-chain acyl-coenzyme A dehydrogenase deficiency, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    palmitoyltransferase I deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, this information is not typically available during differential diagnosis.",
"   </p>",
"   <p>",
"    Diagnostic liver biopsy is rarely performed because the clinical diagnosis is usually reasonably certain, the information gained would not change management (ie, delivery of the fetus), and the procedure exposes the mother and pregnancy to additional risks (",
"    <a class=\"graphic graphic_picture graphicRef69691 \" href=\"UTD.htm?9/26/9639\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia, anemia, and renal failure occurring late in pregnancy can also occur in hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. TTP-HUS should be considered in all pregnant women with severe thrombocytopenia, severe anemia, and elevated LDH levels with minimal elevation of AST [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/21\">",
"     21",
"    </a>",
"    ]. The distinction between TTP-HUS and severe preeclampsia or HELLP is important for therapeutic and prognostic reasons. However, the clinical and histologic features are so similar that establishing the correct diagnosis is often difficult; furthermore, these disorders may occur concurrently.",
"   </p>",
"   <p>",
"    Time of onset may suggest one disorder over the other. The onset of TTP tends to be earlier in gestation than the onset of preeclampsia or HELLP: about 12 percent of TTP in pregnancy occurs in the first trimester, 56 percent in the second trimester, and 33 percent in the third",
"    <span class=\"nowrap\">",
"     trimester/postpartum,",
"    </span>",
"    whereas preeclampsia-HELLP does not occur before 20 weeks of gestation and most cases are diagnosed in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A history of proteinuria and hypertension prior to onset of hemolysis, liver abnormalities, and thrombocytopenia favor the diagnosis of preeclampsia, while a high LDH level with only modest elevation of AST favors TTP.",
"   </p>",
"   <p>",
"    The coagulation abnormalities in these disorders are also different. HELLP is associated with thrombocytopenia, and in severe cases, there may be DIC with the attendant prolongation of the PT and aPTT, and reductions in the plasma concentrations of factors V and VIII. In contrast, TTP-HUS is associated with isolated platelet consumption; thus, although thrombocytopenia is seen, the other findings are typically absent. A peripheral blood smear can also be useful. The percentage of schistocytes on peripheral smear is often higher in TTP (2 to 5 percent) than in HELLP (less than 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/21\">",
"     21",
"    </a>",
"    ]. Lastly, von Willebrand factor-cleaving protease (ADAMTS-13) activity &lt;5 percent is seen in 33 to 100 percent of women with TTP, but is rare or absent in those with HUS or HELLP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the diagnosis is confirmed, the initial steps in management are to stabilize the mother, assess the fetal condition, and decide whether prompt delivery is indicated. Pregnancies less than 34 weeks of gestation, and those in which the mother is unstable, should be managed in consultation with a maternal-fetal specialist.",
"   </p>",
"   <p>",
"    The cornerstone of therapy is delivery. There is consensus among experts that prompt delivery is indicated for any of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancies &ge;34 weeks of gestation",
"     </li>",
"     <li>",
"      Nonreassuring tests of fetal status (eg, biophysical profile, fetal heart rate testing)",
"     </li>",
"     <li>",
"      Presence of severe maternal disease: multiorgan dysfunction, DIC, liver infarction or hemorrhage, renal failure, or abruptio placenta.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antihypertensive drugs are used to treat severe hypertension. Hypertension can usually be controlled (blood pressure less than",
"    <span class=\"nowrap\">",
"     160/105",
"    </span>",
"    mmHg) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61476 \" href=\"UTD.htm?4/10/4267\">",
"     table 5",
"    </a>",
"    ), or, in severe cases, with sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is given intravenously to prevent convulsions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link&amp;anchor=H22#H22\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Magnesium regimen and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet transfusion is indicated if there is significant maternal bleeding (spontaneous or from surgical incisions), or if the platelet count is less than 20,000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    If cesarean delivery is planned, then some experts recommend platelet transfusion, as necessary, to achieve a preoperative platelet count greater than 40,000 to 50,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558384448#H558384448\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Preparation for an invasive procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Route of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal delivery is desirable for women in labor or with ruptured membranes and a vertex presenting infant, regardless of gestational age. Labor can be induced in women with favorable cervices or pregnancies at least 30 to 32 weeks of gestation. Cesarean delivery is performed for the usual obstetrical indications (eg, breech, nonreassuring fetal status). However, we feel cesarean delivery is probably preferable in pregnancies less than 30 to 32 weeks of gestation if the cervix is unfavorable for induction, especially if there are signs of fetal compromise (growth restriction, abruptio placenta, oligohydramnios). Induction of these pregnancies generally has a high failure rate and is often prolonged, thereby potentially exposing the mother and fetus to a higher risk of complications from severe HELLP syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the high risk of subfascial and wound hematoma in these women, some surgeons place a subfascial drain and leave the incision open for the first 48 postoperative hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anesthesia/analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids administered intravenously provide some pain relief without risk of maternal bleeding, which may occur with intramuscular or neuraxial administration or nerve block. However, there is no contraindication to perineal infiltration of an anesthetic for performing an episiotomy or repairing the perineum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pregnancies less than 34 weeks of gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the maternal and fetal status are reassuring, we administer a course of glucocorticoids before delivering pregnancies complicated by HELLP syndrome at less than 34 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ]. We do not advise attempts to delay delivery beyond 48 hours because disease progression usually occurs, sometimes with rapid maternal deterioration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data on the outcome of expectant management of HELLP syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study treated 128 preeclamptic patients with HELLP under 34 weeks with volume expansion and pharmacologic vasodilatation under invasive hemodynamic monitoring in an attempt to prolong pregnancy and thereby enhance fetal maturity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/23\">",
"       23",
"      </a>",
"      ]. Delivery occurred in",
"      <span class=\"nowrap\">",
"       22/128",
"      </span>",
"      (17 percent) of patients within 48 hours; the remaining patients had a median prolongation of pregnancy of 15 days and more than half",
"      <span class=\"nowrap\">",
"       (55/102)",
"      </span>",
"      of these women had complete reversal of their laboratory abnormalities. There was no maternal mortality or serious maternal morbidity, but 11 fetal and 7 neonatal deaths occurred.",
"     </li>",
"     <li>",
"      In another series of 41 women with HELLP, &lt;35 weeks of gestation were managed expectantly [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/24\">",
"       24",
"      </a>",
"      ]. Delivery occurred with 48 hours in",
"      <span class=\"nowrap\">",
"       14/41",
"      </span>",
"      (34 percent), the remaining patients had a median prolongation of pregnancy of three days and more than half",
"      <span class=\"nowrap\">",
"       (15/27)",
"      </span>",
"      had compete reversal of their laboratory abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/24\">",
"       24",
"      </a>",
"      ]. There were 10 fetal deaths.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies show that the laboratory abnormalities of HELLP syndrome will reverse in a subgroup of patients managed expectantly and that serious maternal complications are uncommon with careful maternal monitoring. However, the aim of expectant management is to improve neonatal morbidity and mortality. There is no high quality evidence demonstrating that overall perinatal outcome is improved with expectant management compared with pregnancies delivered after a course of glucocorticoids, and there are no maternal benefits from expectant management. Therefore, expectant management remains an investigational approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Role of dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational studies and small randomized trials suggested use of glucocorticoids may be associated with more rapid improvement in laboratory and clinical parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. These findings were not supported by subsequent large, well-designed randomized, double-blind, placebo-controlled clinical trials evaluating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to improve maternal outcome in patients with HELLP syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, a total of 132 women over 20 weeks of gestation with HELLP syndrome (60 antepartum, 72 postpartum) were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (10 mg intravenously every 12 hours until delivery and three additional doses after delivery) or placebo; postpartum women only received the postpartum doses or placebo. All patients had platelet counts less than 100,000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      AST &gt;70",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      and lactic dehydrogenase &gt;600",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"      The major findings of this trial were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      did not reduce the duration of hospitalization, the rate of platelet or fresh frozen plasma transfusion, or maternal complications (acute renal failure, pulmonary edema).",
"     </li>",
"     <li>",
"      The time of recovery of laboratory tests was not shortened by treatment",
"     </li>",
"     <li>",
"      However, subgroup analysis noted that patients with severe HELLP (platelet count &lt;50,000",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      had faster platelet count recovery and shorter hospitalization than controls. We believe that this finding requires further investigation in prospective trials, given that the analysis was unplanned and the severity of disease was not taken into account at randomization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the second trial, 114 postpartum women with HELLP syndrome were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (10 mg) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/30\">",
"       30",
"      </a>",
"      ]. Use of dexamethasone did not accelerate postpartum recovery of patients with HELLP syndrome: there was no difference between drug and placebo groups in the resolution of laboratory or clinical parameters, frequency of maternal complications, need for rescue therapy, or length of hospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a Cochrane review of 11 trials comparing corticosteroids with",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment in women with HELLP syndrome found no difference between groups in rates of maternal death, maternal death or severe maternal morbidity, or",
"    <span class=\"nowrap\">",
"     perinatal/infant",
"    </span>",
"    death and concluded there was no clear evidence of benefit on substantive clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings, some investigators continue to recommend use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with platelet counts less than 100,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    based on their clinical experience and relatively consistent findings from multiple observational studies and small randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management of hepatic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked elevations in serum aminotransferases are not typical of uncomplicated HELLP; when they occur, the possibility of hepatic infarction, subcapsular hematoma, or viral hepatitis should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hepatic infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked elevation in serum aminotransferases (usually 1000 to 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or higher) associated with right upper quadrant pain and fever is characteristic of hepatic infarction; this diagnosis can be confirmed by hepatic imaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68521 \" href=\"UTD.htm?21/58/22433\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/33\">",
"     33",
"    </a>",
"    ]. Follow-up imaging after delivery typically demonstrates resolution of the infarcts. These patients may have an underlying procoagulant state, such as the antiphospholipid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=see_link\">",
"     \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hepatic hematoma and rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP may be complicated by hepatic rupture with development of a hematoma beneath Glisson's capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5,9,36,37\">",
"     5,9,36,37",
"    </a>",
"    ]. Histology of the liver adjacent to the rupture shows periportal hemorrhage and fibrin deposition, along with a neutrophilic infiltrate, suggestive of hepatic preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"     5",
"    </a>",
"    ]. The hematoma may remain contained, or rupture, with resulting hemorrhage into the peritoneal cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68521 \" href=\"UTD.htm?21/58/22433\">",
"     image 1",
"    </a>",
"    ). A hepatic hematoma rarely occurs in the apparent absence of preeclampsia or HELLP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who develop a hepatic hematoma typically have epigastric pain and many have severe thrombocytopenia, shoulder pain, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/9\">",
"     9",
"    </a>",
"    ]. If hepatic rupture occurs, swelling of the abdomen from hemoperitoneum and shock rapidly ensue. The aminotransferases are usually modestly elevated, but values of 4000 to 5000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    can occasionally be seen. Imaging using CT or MR is more dependable than ultrasonography for detecting these lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86843 \" href=\"UTD.htm?15/57/16275\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68521 \" href=\"UTD.htm?21/58/22433\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of a contained hematoma is to support the patient with volume replacement and blood transfusion, as needed . If the size of the hematoma remains stable and her laboratory abnormalities are resolving, the patient may be discharged home with outpatient follow-up. It may take months for the hematoma to resolve completely [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous embolization of the hepatic arteries is a reasonable first-line therapy of hepatic rupture in women who are hemodynamically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Surgical intervention is indicated if there is hemodynamic instability, persistent bleeding, increasing pain, or continued expansion of the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/41\">",
"     41",
"    </a>",
"    ]. A team experienced in liver trauma surgery should be consulted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/42\">",
"     42",
"    </a>",
"    ]. Operative management includes packing, drainage, hepatic artery ligation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resection of affected areas of the liver. For patients with intractable hemorrhage despite these interventions, administration of recombinant factor VIIa [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/43\">",
"     43",
"    </a>",
"    ] and liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/44-47\">",
"     44-47",
"    </a>",
"    ] have been successful in case reports.",
"   </p>",
"   <p>",
"    Patients who survive have no hepatic sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSTPARTUM COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory values may initially worsen following delivery. The time course of recovery from HELLP was evaluated in a series of 158 women with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/18\">",
"     18",
"    </a>",
"    ]. Decreasing platelet counts continued until 24 to 48 hours after delivery, while serum LDH concentration usually peaked 24 to 48 hours postpartum. In all patients who recovered, a platelet count greater than 100,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    was achieved spontaneously by the sixth postpartum day or within 72 hours of the platelet nadir. An upward trend in platelet count and a downward trend in LDH concentration should be seen by the fourth postpartum day in the absence of complications. Others have reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery can be delayed in women with particularly severe disease, such as those with DIC, platelet count less than 20,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    renal dysfunction, or ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7,49\">",
"     7,49",
"    </a>",
"    ]. These women are at risk of developing pulmonary edema and renal failure (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OUTCOME AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP syndrome is associated with a variety of maternal morbidities, which can rarely result in a fatal outcome. The risk of serious morbidity correlates with increasing severity of maternal symptoms and laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2300817\">",
"    <span class=\"h3\">",
"     Maternal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome for mothers with HELLP is generally good; however, serious complications are relatively common. In our series of 437 women with HELLP syndrome at a tertiary care facility, the following complications were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DIC &mdash; 21 percent",
"     </li>",
"     <li>",
"      Abruptio placentae &mdash; 16 percent",
"     </li>",
"     <li>",
"      Acute renal failure &mdash; 8 percent",
"     </li>",
"     <li>",
"      Pulmonary edema &mdash; 6 percent",
"     </li>",
"     <li>",
"      Subcapsular liver hematoma &mdash; 1 percent",
"     </li>",
"     <li>",
"      Retinal detachment &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, 55 percent of the patients required transfusions with blood or blood products, and 2 percent required laparotomies for major intraabdominal bleeding. Four women (1 percent) died.",
"   </p>",
"   <p>",
"    These complications are interdependent: abruptio placentae is a common obstetrical etiology of DIC, which, in turn, may induce acute renal failure. Acute renal failure may lead to pulmonary edema.",
"   </p>",
"   <p>",
"    Additional complications that have been reported in other series include: adult respiratory distress syndrome, sepsis, and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Wound complications secondary to bleeding and hematomas are common in women with thrombocytopenia.",
"   </p>",
"   <p>",
"    Although most liver function tests (AST, LDH, and conjugated bilirubin) return to normal postpartum, in one report, total bilirubin levels were elevated in 11 (20 percent) of the women who had liver function tests checked 3 to 101 months after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HELLP syndrome with or without renal failure does not affect long-term renal function",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/53,54\">",
"      53,54",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2300824\">",
"    <span class=\"h3\">",
"     Fetus/neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal/neonatal",
"    and long-term prognosis are most strongly associated with gestational age at delivery and birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/55-63\">",
"     55-63",
"    </a>",
"    ]. Maternal laboratory parameters do not predict fetal mortality. Prematurity is common (70 percent), and may be complicated by intrauterine growth restriction and sequelae of abruptio placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/56\">",
"     56",
"    </a>",
"    ]. The overall perinatal mortality is 7 to 20 percent; prematurity, intrauterine growth restriction, and abruptio placentae are the leading causes of perinatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"     7",
"    </a>",
"    ]. Leukopenia, neutropenia, and thrombocytopenia may be observed, but appear to be related to intrauterine growth restriction, prematurity, and maternal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/57\">",
"     57",
"    </a>",
"    ]. Maternal HELLP does not affect",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    liver function. .",
"   </p>",
"   <p>",
"    A prospective analysis of the genotypes in mothers and offspring of pregnancies complicated by acute fatty liver of pregnancy (AFLP) or HELLP syndrome suggested that 15 to 20 percent of pregnancies complicated by AFLP and less than 2 percent of pregnancies complicated by HELLP syndrome are associated with fetal long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHAD) deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/13,64\">",
"     13,64",
"    </a>",
"    ]. However, these high rates may be the result of referral bias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Recurrence in subsequent pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data defining the recurrence risk of HELLP syndrome are sparse. In three series including almost 400 pregnancies in women with a history of this syndrome, the rate of recurrence was only 2 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]; however, recurrence rates (mostly partial HELLP syndrome) of 24 to 27 percent have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/20,68\">",
"     20,68",
"    </a>",
"    ]. Rare cases of recurrent hepatic rupture in a subsequent pregnancy have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/36,69\">",
"     36,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, women with a history of HELLP syndrome are at high risk for developing preeclampsia in a subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/65,66,68\">",
"     65,66,68",
"    </a>",
"    ]. In one series of 152 such women with 212 subsequent pregnancies, the incidence of preeclampsia varied from 19 percent in normotensive women to 75 percent in those with underlying hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/65\">",
"     65",
"    </a>",
"    ]. Another report was limited to 48 women with second trimester HELLP syndrome who had 62 subsequent pregnancies that progressed beyond 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17897/abstract/66\">",
"     66",
"    </a>",
"    ]. Preeclampsia occurred in 27 of 52 subsequent pregnancies in normotensive women and 7 of 10 pregnancies in women with chronic hypertension.",
"   </p>",
"   <p>",
"    There is no evidence that any therapy prevents recurrent HELLP syndrome, but data are limited. Use of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for prevention of preeclampsia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of preeclampsia\", section on 'Antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=see_link\">",
"       \"Patient information: HELLP syndrome (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       \"Patient information: High blood pressure and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HELLP syndrome (hemolysis with a microangiopathic blood smear, elevated liver enzymes, and a low platelet count) develops in approximately 1 of 1000 pregnancies overall and 10 to 20 percent of pregnancies with severe",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia.",
"      </span>",
"      The majority of cases are diagnosed between 28 and 36 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and onset of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common clinical presentation is abdominal pain and tenderness in the midepigastrium, right upper quadrant, or below the sternum. Many patients also have nausea, vomiting, and malaise, which may be mistaken for a nonspecific viral illness or viral hepatitis. Hypertension and proteinuria are present in approximately 85 percent of cases, but may be absent in women with otherwise severe HELLP syndrome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon the presence of all of the following characteristic laboratory findings in patients of appropriate gestational age: (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia with characteristic schistocytes on blood smear (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      ). Other signs suggestive of hemolysis include an elevated indirect bilirubin and a low serum haptoglobin concentration (&le;25",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count &lt;100,000",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"     </li>",
"     <li>",
"      Total bilirubin &gt;1.2",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Serum aspartate aminotransferase (AST) &gt;70",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"     </li>",
"     <li>",
"      Lactate dehydrogenase (LDH) &gt;2 times the upper limit of normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The outcome for mothers with HELLP syndrome is generally good, but serious complications such as abruptio placentae, acute renal failure, subcapsular liver hematoma, and retinal detachment may occur. The risk of recurrence in future pregnancies appears to be increased. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Outcome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Recurrence in subsequent pregnancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe maternal disease (eg, multiorgan dysfunction, disseminated intravascular coagulation, liver infarction or hemorrhage, renal failure, abruptio placenta) or nonreassuring fetal status is an indication for prompt delivery regardless of gestational age. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies &ge;34 weeks of gestation, we recommend delivery rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In this population, the potential risks of preterm birth are outweighed by the risks associated with HELLP syndrome. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies less than 34 weeks of gestation in which maternal and fetal status is reassuring, we suggest delivery after a course of glucocorticoids to accelerate fetal pulmonary maturity rather than expectant management or prompt delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although the laboratory abnormalities of HELLP syndrome will reverse in a subgroup of patients managed expectantly and serious maternal complications are uncommon with careful maternal monitoring, there is no high quality evidence showing that overall perinatal outcome is improved with expectant management. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pregnancies less than 34 weeks of gestation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For gestations less than 30 to 32 weeks with an unfavorable cervix, we suggest cesarean delivery to avoid a potentially long induction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Route of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not giving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for treatment of HELLP syndrome (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Dexamethasone does not accelerate resolution of laboratory abnormalities or reduce the risk of maternal complications. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Role of dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/1\">",
"      Stone JH. HELLP syndrome: hemolysis, elevated liver enzymes, and low platelets. JAMA 1998; 280:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/2\">",
"      Sibai BM, Taslimi MM, el-Nazer A, et al. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986; 155:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/3\">",
"      Reubinoff BE, Schenker JG. HELLP syndrome--a syndrome of hemolysis, elevated liver enzymes and low platelet count--complicating preeclampsia-eclampsia. Int J Gynaecol Obstet 1991; 36:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/4\">",
"      Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990; 162:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/5\">",
"      Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/6\">",
"      Catanzarite VA, Steinberg SM, Mosley CA, et al. Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and lactate dehydrogenase levels: high risk for maternal death. Am J Perinatol 1995; 12:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/7\">",
"      Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004; 103:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/8\">",
"      Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth 2009; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/9\">",
"      Barton JR, Sibai BM. Hepatic imaging in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count). Am J Obstet Gynecol 1996; 174:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/10\">",
"      Nunes JO, Turner MA, Fulcher AS. Abdominal imaging features of HELLP syndrome: a 10-year retrospective review. AJR Am J Roentgenol 2005; 185:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/11\">",
"      Pereira SP, O'Donohue J, Wendon J, Williams R. Maternal and perinatal outcome in severe pregnancy-related liver disease. Hepatology 1997; 26:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/12\">",
"      Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999; 340:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/13\">",
"      Yang Z, Yamada J, Zhao Y, et al. Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease. JAMA 2002; 288:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/14\">",
"      Innes AM, Seargeant LE, Balachandra K, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000; 47:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/15\">",
"      Matern D, Hart P, Murtha AP, et al. Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 2001; 138:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/16\">",
"      Sibai BM, Ramadan MK. Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets. Am J Obstet Gynecol 1993; 168:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/17\">",
"      Weiner CP. Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 1987; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/18\">",
"      Martin JN Jr, Blake PG, Perry KG Jr, et al. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991; 164:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/19\">",
"      Egerman RS, Witlin AG, Friedman SA, Sibai BM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases. Am J Obstet Gynecol 1996; 175:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/20\">",
"      Sullivan CA, Magann EF, Perry KG Jr, et al. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 1994; 171:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/21\">",
"      Stella CL, Dacus J, Guzman E, et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol 2009; 200:381.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/22\">",
"      Martin JN Jr, Bailey AP, Rehberg JF, et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol 2008; 199:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/23\">",
"      Visser W, Wallenburg HC. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 1995; 102:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/24\">",
"      van Pampus MG, Wolf H, Westenberg SM, et al. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1998; 76:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/25\">",
"      O'Brien JM, Shumate SA, Satchwell SL, et al. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol 2002; 186:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/26\">",
"      Matchaba P, Moodley J. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst Rev 2004; :CD002076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/27\">",
"      Isler CM, Barrilleaux PS, Magann EF, et al. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001; 184:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/28\">",
"      Martin JN Jr, Thigpen BD, Rose CH, et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003; 189:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/29\">",
"      Fonseca JE, M&eacute;ndez F, Cata&ntilde;o C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/30\">",
"      Katz L, de Amorim MM, Figueiroa JN, Pinto e Silva JL. Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2008; 198:283.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/31\">",
"      Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010; :CD008148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/32\">",
"      Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006; 195:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/33\">",
"      Krueger KJ, Hoffman BJ, Lee WM. Hepatic infarction associated with eclampsia. Am J Gastroenterol 1990; 85:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/34\">",
"      Ilbery M, Jones AR, Sampson J. Lupus anticoagulant and HELLP syndrome complicated by placental abruption, hepatic, dermal and adrenal infarction. Aust N Z J Obstet Gynaecol 1995; 35:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/35\">",
"      Alsulyman OM, Castro MA, Zuckerman E, et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol 1996; 88:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/36\">",
"      Greenstein D, Henderson JM, Boyer TD. Liver hemorrhage: recurrent episodes during pregnancy complicated by preeclampsia. Gastroenterology 1994; 106:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/37\">",
"      Wicke C, Pereira PL, Neeser E, et al. Subcapsular liver hematoma in HELLP syndrome: Evaluation of diagnostic and therapeutic options--a unicenter study. Am J Obstet Gynecol 2004; 190:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/38\">",
"      Schwartz ML, Lien JM. Spontaneous liver hematoma in pregnancy not clearly associated with preeclampsia: a case presentation and literature review. Am J Obstet Gynecol 1997; 176:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/39\">",
"      Rinehart BK, Terrone DA, Magann EF, et al. Preeclampsia-associated hepatic hemorrhage and rupture: mode of management related to maternal and perinatal outcome. Obstet Gynecol Surv 1999; 54:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/40\">",
"      Grand'Maison S, Sauv&eacute; N, Weber F, et al. Hepatic rupture in hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 2012; 119:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/41\">",
"      Wilson RH, Marshall BM. Postpartum rupture of a subcapsular hematoma of the liver. Acta Obstet Gynecol Scand 1992; 71:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/42\">",
"      Stevenson JT, Graham DJ. Hepatic hemorrhage and the HELLP syndrome: a surgeon's perspective. Am Surg 1995; 61:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/43\">",
"      Merchant SH, Mathew P, Vanderjagt TJ, et al. Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet Gynecol 2004; 103:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/44\">",
"      Erhard J, Lange R, Niebel W, et al. Acute liver necrosis in the HELLP syndrome: successful outcome after orthotopic liver transplantation. A case report. Transpl Int 1993; 6:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/45\">",
"      Hunter SK, Martin M, Benda JA, Zlatnik FJ. Liver transplant after massive spontaneous hepatic rupture in pregnancy complicated by preeclampsia. Obstet Gynecol 1995; 85:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/46\">",
"      Araujo AC, Leao MD, Nobrega MH, et al. Characteristics and treatment of hepatic rupture caused by HELLP syndrome. Am J Obstet Gynecol 2006; 195:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/47\">",
"      Zarrinpar A, Farmer DG, Ghobrial RM, et al. Liver transplantation for HELLP syndrome. Am Surg 2007; 73:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/48\">",
"      Hupuczi P, Nagy B, Sziller I, et al. Characteristic laboratory changes in pregnancies complicated by HELLP syndrome. Hypertens Pregnancy 2007; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/49\">",
"      Martin JN Jr, Blake PG, Lowry SL, et al. Pregnancy complicated by preeclampsia-eclampsia with the syndrome of hemolysis, elevated liver enzymes, and low platelet count: how rapid is postpartum recovery? Obstet Gynecol 1990; 76:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/50\">",
"      Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1996; 175:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/51\">",
"      Martin JN Jr, Rinehart BK, May WL, et al. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999; 180:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/52\">",
"      Knapen MF, van Altena AM, Peters WH, et al. Liver function following pregnancy complicated by the HELLP syndrome. Br J Obstet Gynaecol 1998; 105:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/53\">",
"      Jacquemyn Y, Jochems L, Duiker E, et al. Long-term renal function after HELLP syndrome. Gynecol Obstet Invest 2004; 57:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/54\">",
"      Drakeley AJ, Le Roux PA, Anthony J, Penny J. Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit. Am J Obstet Gynecol 2002; 186:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/55\">",
"      Abramovici D, Friedman SA, Mercer BM, et al. Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999; 180:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/56\">",
"      Sibai BM, Spinnato JA, Watson DL, et al. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol 1984; 64:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/57\">",
"      Harms K, Rath W, Herting E, Kuhn W. Maternal hemolysis, elevated liver enzymes, low platelet count, and neonatal outcome. Am J Perinatol 1995; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/58\">",
"      Singhal N, Amin HJ, Pollard JK, et al. Maternal haemolysis, elevated liver enzymes and low platelets syndrome: perinatal and neurodevelopmental neonatal outcomes for infants weighing less than 1250 g. J Paediatr Child Health 2004; 40:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/59\">",
"      D&ouml;tsch J, Hohmann M, K&uuml;hl PG. Neonatal morbidity and mortality associated with maternal haemolysis elevated liver enzymes and low platelets syndrome. Eur J Pediatr 1997; 156:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/60\">",
"      Gortner L, Pohlandt F, Bartmann P, et al. Short-term outcome in infants with birth weights less than 1750 g born to mothers with HELLP syndrome. J Perinat Med 1992; 20:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/61\">",
"      K&auml;ndler C, Kevekordes B, Zenker M, et al. Prognosis of children born to mothers with HELLP-syndrome. J Perinat Med 1998; 26:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/62\">",
"      Murray D, O'Riordan M, Geary M, et al. The HELLP syndrome: maternal and perinatal outcome. Ir Med J 2001; 94:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/63\">",
"      Guzel AI, Kuyumcuoglu U, Celik Y. Are maternal and fetal parameters related to perinatal mortality in HELLP syndrome? Arch Gynecol Obstet 2011; 283:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/64\">",
"      Yang Z, Zhao Y, Bennett MJ, et al. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002; 187:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/65\">",
"      Sibai BM, Ramadan MK, Chari RS, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995; 172:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/66\">",
"      Chames MC, Haddad B, Barton JR, et al. Subsequent pregnancy outcome in women with a history of HELLP syndrome at &lt; or = 28 weeks of gestation. Am J Obstet Gynecol 2003; 188:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/67\">",
"      van Pampus MG, Wolf H, Mayruhu G, et al. Long-term follow-up in patients with a history of (H)ELLP syndrome. Hypertens Pregnancy 2001; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/68\">",
"      Habli M, Eftekhari N, Wiebracht E, et al. Long-term maternal and subsequent pregnancy outcomes 5 years after hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Am J Obstet Gynecol 2009; 201:385.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17897/abstract/69\">",
"      W&uuml;st MD, Bolte AC, de Vries JI, et al. Pregnancy outcome after previous pregnancy complicated by hepatic rupture. Hypertens Pregnancy 2004; 23:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6778 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17897=[""].join("\n");
var outline_f17_30_17897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND ONSET OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Route of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anesthesia/analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pregnancies less than 34 weeks of gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Role of dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management of hepatic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hepatic infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hepatic hematoma and rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSTPARTUM COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OUTCOME AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2300817\">",
"      - Maternal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2300824\">",
"      - Fetus/neonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Recurrence in subsequent pregnancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6778\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6778|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/58/22433\" title=\"diagnostic image 1\">",
"      Hepatic hematoma rupture MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/57/16275\" title=\"diagnostic image 2\">",
"      Subcapsular liver hematoma on MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6778|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/14/12514\" title=\"figure 1\">",
"      Liver disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6778|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/26/9639\" title=\"picture 2\">",
"      Liver in HELLP Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6778|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/60/43979\" title=\"table 2\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/6/7275\" title=\"table 3\">",
"      Frequency signs symptoms HELLP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/31/32252\" title=\"table 4\">",
"      TTP HUS HELLP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/10/4267\" title=\"table 5\">",
"      Treatment htn preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=related_link\">",
"      Patient information: HELLP syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_30_17898="Management of the patient with severe COPD and cardiovascular disease";
var content_f17_30_17898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the patient with severe COPD and cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Imre Noth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Gregory A Schmidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17898/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/30/17898/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/30/17898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), which includes coronary heart disease, peripheral artery disease, and cerebrovascular disease, share tobacco abuse as a major risk factor. Thus, these two disorders commonly coexist. In addition, CVD is a leading cause of death among patients with COPD.",
"   </p>",
"   <p>",
"    The management of patients with severe COPD and CVD will be reviewed here. The diagnosis and management of COPD and coronary heart disease occurring independently are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link\">",
"     \"Epidemiology of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COPD/CVD RELATIONSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist, and the presence of one can affect outcomes in the other. As symptoms can overlap, differentiating the relative contributions of these diseases to a given patient&rsquo;s symptoms can be challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104140482\">",
"    <span class=\"h2\">",
"     Coexistence of COPD and CVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequent coexistence of COPD and CVD has been observed in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As an example, a study from a large United Kingdom database of more than 1.2 million patients over age 35 identified almost 30,000 patients with COPD; these patients were nearly five times more likely to have cardiovascular disease than those without COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/1\">",
"     1",
"    </a>",
"    ]. In a separate study of 351 patients with advanced COPD, clinically significant coronary disease was identified by angiography in 60 percent and was occult in 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104140467\">",
"    <span class=\"h2\">",
"     Impact of co-morbid disease on outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of observational studies have found that the coexistence of COPD and cardiovascular disease has an important impact on clinical outcomes.",
"   </p>",
"   <p>",
"    Cardiovascular morbidity and mortality in patients with COPD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 25,857 patients with COPD, an increased risk of myocardial infarction (2.27-fold, 95% CI, 1.1-4.7) and stroke (1.26-fold, 95% CI, 1.0-1.6) was noted in the days to weeks after an exacerbation of COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a drug trial that included 911 patients with moderate to severe COPD (forced expiratory volume in one second [FEV",
"      <sub>",
"       1",
"      </sub>",
"      ] &lt;60 percent predicted), the cause of death was cardiovascular in at least 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It has been estimated that for every 10 percent decrease in FEV",
"      <sub>",
"       1",
"      </sub>",
"      , cardiovascular mortality increases by 28 percent and nonfatal coronary events by almost 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effect of COPD on morbidity and mortality in patients with CVD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 3249 patients with an acute ST-elevation myocardial infarction, COPD was a strong independent predictor of the composite end-point of death or cardiogenic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 14,346 patients who underwent percutaneous coronary intervention (PCI) at a single center, COPD was a significant independent risk factor for overall mortality, cardiac mortality, and myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A separate study of patients undergoing PCI compared subjects with and without COPD (860 and 10,048, respectively). The patients with COPD had a lower mean ejection fraction and a greater number of significant coronary lesions. The COPD group also carried a higher mortality rate and a greater rate of repeat revascularization within the subsequent year [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    COPD is also a risk factor for supraventricular and ventricular arrhythmias. The risk factors for and management of arrhythmias in patients with COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/21/8538?source=see_link\">",
"     \"Arrhythmias in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104142942\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS OF CHD IN PATIENTS WITH COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of dyspnea and chest tightness are common to COPD and coronary heart disease (CHD). In patients with known COPD, uncontrolled dyspnea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest tightness could be due to refractory COPD or concomitant CHD. Due to the frequent co-existence of these diseases and the potential diagnostic uncertainty of the symptoms, physicians caring for patients with COPD need to have a low threshold for performing additional diagnostic testing to identify CHD. We typically perform a baseline electrocardiogram and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress imaging, as exercise limitations may preclude exercise stress testing, and potential bronchoconstriction is often a contraindication to vasodilator radionuclide myocardial perfusion imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=see_link\">",
"     \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since exacerbations of both COPD and CHD are often signaled by dyspnea, patients and clinicians may find it challenging to know which disease requires urgent treatment. Classic symptoms of a COPD flare (eg, dyspnea, cough, wheezing, and change in sputum) may point correctly to the lung, while new electrocardiographic signs of ischemia may prove that the heart is the culprit. Alternatively, both organ systems may be involved and difficult to distinguish. In a study examining the ability of N-terminal pro-brain natriuretic peptide (NT pro-BNP) and troponin T to differentiate an acute exacerbation of COPD from left heart dysfunction, 46 of the 148 patients (31 percent) were judged to have both a COPD exacerbation and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"     \"Evaluation of the adult with dyspnea in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevated serum cardiac troponin frequently, but not always, indicates the presence of coronary artery disease. Among 242 patients admitted for an exacerbation of COPD, 24 had a raised troponin and 20 had chest pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serial ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/11\">",
"     11",
"    </a>",
"    ]. However, neither chest pain nor serial ECG changes were statistically associated with elevated troponin, suggesting that a raised troponin in the context of a COPD exacerbation is not necessarily indicative of myocardial injury. In a separate study, highly sensitive cardiac troponin (hs-cTnT) was measured in 50 patients admitted with an acute exacerbation of COPD and 124 stable patients in a pulmonary rehabilitation hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/12\">",
"     12",
"    </a>",
"    ]. The ratio of hs-cTnT in those with a COPD exacerbation was significantly higher than those with stable COPD, ratio 5.67 (95% CI 4.0-7.86). However, the specific determinants of hs-cTnT elevation were unclear, as neither hypoxic vasoconstriction nor underlying CVD were statistically associated with the increase in hs-cTnT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=see_link\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of undiagnosed heart failure was examined in a cross-sectional study of 244 older adults with COPD based on the initial Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/13\">",
"     13",
"    </a>",
"    ]. Previously unrecognized heart failure was identified in 21 percent, and ischemic heart disease was judged to be the most common cause of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12892415\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonpharmacologic therapies may help reduce symptoms and improve quality of life in patients with concomitant severe COPD and CVD. These interventions have been evaluated in patients with either COPD or CVD, but have not been examined extensively when both diseases are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12892425\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation is essential to improving outcomes in patients with comorbid COPD and CVD. Behavioral and pharmacologic interventions (eg, nicotine replacement therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    ) to help patients with smoking cessation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nicotine replacement therapy is indicated for ambulatory patients with COPD despite the presence of CVD. The risk of coronary events (eg, cardiac arrest, myocardial infarction, admission to the hospital for CVD events) is lower among users of nicotine replacement than placebo. The issue of whether nicotine replacement can be started during a hospitalization for myocardial infarction has not been well studied, but cautious initiation during the hospitalization or at the time of discharge is thought to be reasonable. The use of nicotine replacement in patients with CAD or acute myocardial infarction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/23/30073?source=see_link&amp;anchor=H18#H18\">",
"     \"Cardiovascular effects of nicotine\", section on 'Safety of nicotine replacement therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12892461\">",
"    <span class=\"h2\">",
"     Cardiopulmonary rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies and systematic reviews have demonstrated the benefits of exercise training in patients with either COPD or CVD, but data are more limited regarding the benefit of exercise training in patients with comorbid COPD and CAD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/14\">",
"     14",
"    </a>",
"    ]. Observational studies have yielded conflicting results regarding the effect of comorbid CAD on the response to pulmonary rehabilitation. These studies are described in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link&amp;anchor=H6#H6\">",
"     \"Pulmonary rehabilitation in COPD\", section on 'Effect of comorbidities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe COPD typically have a severely limited exercise capacity, but can often achieve an increase in their activity level with pulmonary rehabilitation. We typically refer patients to a pulmonary rehabilitation program, unless chest pain or myocardial ischemia is noted on an exercise pretest. These patients are referred for cardiac evaluation and possibly a cardiac rehabilitation program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17705?source=see_link\">",
"     \"Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12892433\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual vaccination against influenza is indicated for patients with severe COPD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H43#H43\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Influenza vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination against pneumococcus is recommended for all individuals &ge;65 years and persons aged 19 to 64 with COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H28#H28\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Vaccinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12892613\">",
"    <span class=\"h2\">",
"     Management of hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with severe COPD, hypoxemia (eg, pulse oxygen saturation &le;88 percent) may be present at rest or be precipitated by exercise, sleep-related hypopneas, a fit of coughing, or noncompliance with home oxygen. When added to the limitations to blood flow caused by coronary stenoses, episodes of hypoxemia can contribute to myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The details of prescribing long-term oxygen therapy are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link&amp;anchor=H5#H5\">",
"     \"Long-term supplemental oxygen therapy\", section on 'Prescribing oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Effect of hypoxemia on the heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration and extent of hypoxemia necessary to produce ischemic changes resulting from coronary lesions is unknown. Mild or brief hypoxemia appears to be unimportant. This was illustrated in a study of 38 patients with ST depression on cardiac stress testing in whom three minutes of breathing a hypoxic mixture to produce an arterial oxygen saturation of 85 percent did not amplify the electrocardiographic signs of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/15\">",
"     15",
"    </a>",
"    ]. Myocardial ischemia appears more likely to worsen when the duration of hypoxemia is longer than five minutes or the degree of hypoxemia is severe (SpO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoxemia may also increase the risk of cardiac arrhythmia. A high incidence of ventricular and supraventricular arrhythmia, particularly multifocal atrial tachycardia (MAT), has been described in patients with COPD with either stable disease or an acute exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Arrhythmias in COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/21/8538?source=see_link\">",
"     \"Arrhythmias in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Indications for supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen therapy can correct hypoxemia that is associated with stable COPD or a COPD exacerbation. Supplemental oxygen therapy can also relieve hypoxic pulmonary vasoconstriction and reverse tissue hypoxia. The enhanced oxygen content of arterial blood maintains total body oxygen delivery and allows the cardiac output to fall, reducing left ventricular work. This latter effect is probably one of the reasons that long-term supplemental oxygen improves survival in patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link&amp;anchor=H2#H2\">",
"     \"Long-term supplemental oxygen therapy\", section on 'Benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that higher than usual arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) may confer additional benefit in patients with ongoing myocardial ischemia. Animal studies of oxygen supplementation demonstrate that hyperoxic states improve both function and blood flow distribution in ischemic myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/22\">",
"     22",
"    </a>",
"    ]. Although often well tolerated, these higher fractions of inspired oxygen can lead to exacerbation of hypercapnia in patients with COPD and are not usually given clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current indications for continuous long-term oxygen therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PaO",
"      <sub>",
"       2",
"      </sub>",
"      &le;55 mmHg or pulse oxygen saturation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      ) &le;88 percent during rest",
"     </li>",
"     <li>",
"      PaO",
"      <sub>",
"       2",
"      </sub>",
"      between 56 to 59 mmHg (SpO",
"      <sub>",
"       2",
"      </sub>",
"      of 89 percent) combined with evidence of cor pulmonale, right heart failure, or erythrocytosis (hematocrit &gt;56 percent)",
"     </li>",
"     <li>",
"      PaO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;60 mmHg or SpO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;90 percent with \"compelling medical justification\"; including significant coronary heart disease or active cardiac ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term oxygen therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen supplementation may raise the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    slightly in hypercapnic patients, but this is generally well tolerated. The above studies indicate that the risks of withholding oxygen or giving it too sparingly significantly outweigh any detrimental effects of the higher PaCO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/19-21,25\">",
"     19-21,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4096341\">",
"    <span class=\"h2\">",
"     Noninvasive positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) can provide temporary ventilatory support in selected patients with acute cardiogenic pulmonary edema or acute hypercapnic respiratory failure due to a COPD exacerbation. It is an attractive option for patients who have severe dyspnea that may be due to COPD or CVD, buying additional time for diagnostic studies (eg, to determine whether symptoms are due to COPD, CVD, or both) and empiric therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT OF COPD IN PATIENTS WITH CVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of treatment for severe COPD include the inhaled anticholinergic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13764?source=see_link\">",
"     aclidinium",
"    </a>",
"    ), inhaled selective beta-2 agonists, and inhaled glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35060?source=see_link\">",
"     Roflumilast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    are less commonly used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81300262\">",
"    <span class=\"h2\">",
"     Inhaled anticholinergic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled short-acting anticholinergic agents (eg,",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/ipratropium-drug-information?source=see_link\">",
"     ipratropium",
"    </a>",
"    &nbsp;bromide) are used with inhaled short-acting beta adrenergic agonists to treat acute symptoms of COPD. The longer acting agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13764?source=see_link\">",
"     aclidinium",
"    </a>",
"    ) are key components of the management of moderate to severe COPD. Concern has been raised regarding possible adverse cardiovascular effects of the inhaled anticholinergic medications, and conflicting findings have been reported in various studies and meta-analyses.",
"   </p>",
"   <p>",
"    Data that suggest a reduction or no increase in cardiovascular mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest randomized trial to address this question was the Understanding Potential Long-Term Impacts on Function with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       Tiotropium",
"      </a>",
"      (UPLIFT) trial, in which 5993 patients with COPD were randomly assigned to tiotropium or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/26\">",
"       26",
"      </a>",
"      ]. A reduction in mortality related to cardiac disorders was found in the tiotropium group compared with placebo (0.25 versus 0.30 deaths per 100 patient years, respectively) with a hazard ratio of 0.86 (95% CI 0.75-0.99). The UPLIFT trial is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=see_link&amp;anchor=H12#H12\">",
"       \"Role of anticholinergic therapy in COPD\", section on 'Tiotropium'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of cardiovascular events was further examined using a clinical trial safety database for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      , which monitored 19,545 patients with moderate to severe COPD (including the UPLIFT data) who were randomly assigned to tiotropium or placebo in a total of 30 trials [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/27\">",
"       27",
"      </a>",
"      ]. No increase in all-cause mortality, cardiovascular mortality, or cardiovascular events was found in the tiotropium group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data suggesting a possible increase in the risk for cardiovascular events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk of cardiovascular events was identified in a cohort study of 82,717 United States veterans with COPD. The hazard ratio for cardiovascular events was increased among those with four or fewer prescriptions for a month of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      and among those with more than four, 1.40 [95% CI 1.30-1.51] and 1.23 [1.13-1.36], respectively. However, the case cohort design places limits on the interpretation of these findings.",
"     </li>",
"     <li>",
"      The Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) trial demonstrated fewer fatal cardiovascular events in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      arm than the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      arm. However, it was not designed as mortality trial and lacked adequate adjudication of fatal outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subgroup analysis of a meta-analysis comparing the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      dry powder (available in the United States) with the Respimat soft mist inhaler found proportionately fewer deaths with the dry powder inhaler [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/29\">",
"       29",
"      </a>",
"      ]. However, methodologic concerns related to uneven study discontinuation limit the conclusions that can be drawn from this trial. One possible explanation for the observed higher mortality associated with the Respimat device is that higher peak plasma concentrations of tiotropium are achieved with that device than with the dry powder Handihaler.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility remains that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    have different effects on cardiovascular events, as more studies suggest safety with tiotropium than with ipratropium. Further data on the safety of ipratropium bromide and the tiotropium Respimat among patients with CVD are needed from randomized trials in which cardiovascular endpoints are specifically sought and defined.",
"   </p>",
"   <p>",
"    In the meantime, the majority of patients with severe COPD are treated with a combination of long-acting anticholinergic and long-acting beta agonists, regardless of underlying CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/30\">",
"     30",
"    </a>",
"    ]. Any potential for cardiovascular risk suggested by the above studies should be balanced against the",
"    <strong>",
"     known",
"    </strong>",
"    benefits of these inhaled anticholinergic agents (eg, reduced frequency of exacerbations, fewer hospitalizations, and improved dyspnea). This topic is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=see_link\">",
"     \"Role of anticholinergic therapy in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4096480\">",
"    <span class=\"h2\">",
"     Beta-2 agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inhaled beta-2 agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ) are relatively selective for beta-2 adrenergic receptors. However, the possibility has been raised that mild beta-1 activity associated with these agents might cause the following adverse effects in patients with COPD and CVD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possible induction of arrhythmias by stimulation of cardiac beta-adrenoreceptors",
"     </li>",
"     <li>",
"      Reflex activation of adrenergic mechanisms by causing peripheral vasodilation",
"     </li>",
"     <li>",
"      Downregulation of myocardial beta-2 receptors, potentially worsening heart failure associated with left ventricular systolic dysfunction",
"     </li>",
"     <li>",
"      Provocation of hypokalemia by intracellular translocation of potassium or hypoxemia through worsened matching of ventilation and perfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27291990\">",
"    <span class=\"h3\">",
"     Short-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting inhaled beta agonists are the preferred bronchodilators for treatment of acute symptoms of COPD, based on their rapid onset of action. This choice is unaffected by the presence of CAD. It is reassuring that among 12,090 patients age 55 or older with COPD, short-acting inhaled beta agonists did not increase the risk of fatal or nonfatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/31\">",
"     31",
"    </a>",
"    ]. The management of acute exacerbations of COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\", section on 'Beta adrenergic agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27291983\">",
"    <span class=\"h3\">",
"     Long-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled long-acting beta agonists (LABAs) are widely used for treatment of severe COPD; data are reassuring regarding their safety in patients with CVD. Several studies have specifically evaluated the cardiovascular effects of LABAs. The long-acting agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    has been both safe and effective when given to patients with COPD at a dose of 50 mcg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/32\">",
"     32",
"    </a>",
"    ]; larger doses (100 mcg twice daily) have also proven safe when given for three days to patients with reversible airflow obstruction, producing no significant change in mean heart rate or the number of premature beats and no ECG evidence of myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Toward a Revolution in COPD Health (TORCH) trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    alone, salmeterol plus fluticasone, and placebo in 6112 patients with COPD over three years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/34\">",
"     34",
"    </a>",
"    ]. The frequency of cardiac events was not increased in the salmeterol alone group or the salmeterol plus fluticasone group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some but not all studies have suggested that beta-2 agonists may have an adverse effect in patients with left ventricular dysfunction. In a review of 1529 patients with left ventricular systolic dysfunction (by echocardiography or radionuclide ventriculography), the relative risk of hospitalization for heart failure followed a dose-response relationship with the use of inhaled beta-agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/36\">",
"     36",
"    </a>",
"    ]. In contrast, a retrospective study of 1294 subjects attending a heart failure disease management program did not find an increase in mortality associated with beta-2 agonist use (HR 1.043, 95% CI 0.771 to 1.412) after adjusting for age, gender, smoking, medications, and severity of co-morbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While beta-2 adrenergic agonists have the potential to increase heart rate and may increase cardiac arrhythmias via nonselective beta adrenergic effects, a number of studies have shown a very low to no increased risk of serious arrhythmias with these medications. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/21/8538?source=see_link&amp;anchor=H5#H5\">",
"     \"Arrhythmias in COPD\", section on 'Beta-adrenergic agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Combination inhaled bronchodilator plus glucocorticoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential cardiovascular effects of combination long-acting beta agonist (LABA)-glucocorticoid inhalers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ) have also been investigated, although these studies were not specifically done in patients with CVD. Thus, they provide indirect evidence regarding the safety of these agents in patients with concomitant COPD and CVD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis (10 studies, 10,680 participants) that compared combination inhaled LABA PLUS glucocorticoid with inhaled LABA alone in severe COPD, there was no significant difference in mortality (OR 0.92, 95% CI 0.76-1.11) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/38\">",
"       38",
"      </a>",
"      ]. However, underlying cardiovascular disease was an exclusion criterion for participation, and the rate of cardiovascular events was not examined.",
"     </li>",
"     <li>",
"      In a randomized trial of 723 patients with COPD who were assigned to placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      alone, or both drugs, the incidence of clinically significant ECG abnormalities was comparable among the treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/39\">",
"       39",
"      </a>",
"      ]. There were no safety concerns for combination therapy compared to the individual drugs.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      was also evaluated in the TORCH trial mentioned above [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/34\">",
"       34",
"      </a>",
"      ]. The incidence of cardiovascular events was not increased in this group, compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of combined LABA-glucocorticoid inhaled medications in COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Bronchodilators plus inhaled glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81298178\">",
"    <span class=\"h2\">",
"     Roflumilast",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35060?source=see_link\">",
"     Roflumilast",
"    </a>",
"    is a phosphodiesterase-4 inhibitor that is approved for use in patients with a history of COPD exacerbations. It provides a modest improvement in pulmonary function. Atrial fibrillation and other supraventricular arrhythmias occurred in less than 2 percent of patients in clinical trials, but the trials may not have included patients with known CVD. Concomitant administration of roflumilast and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    to healthy men did not result in adverse cardiovascular effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/40\">",
"     40",
"    </a>",
"    ]. The use of roflumilast in COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H204741580#H204741580\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'PDE-4 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is generally avoided in patients with CAD. While occasionally used in patients with severe COPD for its mild bronchodilating effects and a possible improvement in exercise performance, it has a narrow therapeutic index and is associated with tachycardia and arrhythmias. Administration of theophylline is plagued by an appreciable incidence of side effects, even when serum drug concentrations are in the low therapeutic range. These adverse effects include tachycardia and palpitations, in addition to gastrointestinal upset and headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=see_link\">",
"     \"Role of methylxanthines in the treatment of COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"     \"Theophylline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence of an adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in patients with CVD is largely indirect, but suggests an increased risk of dose-related atrial and ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The contribution of theophylline to the development of arrhythmias in patients with COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/21/8538?source=see_link&amp;anchor=H4#H4\">",
"     \"Arrhythmias in COPD\", section on 'Theophylline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81297784\">",
"    <span class=\"h1\">",
"     TREATMENT OF CVD IN PATIENTS WITH COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of symptomatic CAD in patients with COPD generally follows the same guidelines as for patients without COPD, except that we avoid nonselective beta-blockers in patients with COPD due to concerns about the induction of clinically important bronchoconstriction by nonselective agents. Instead, we typically use a cardioselective beta-blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/44\">",
"     44",
"    </a>",
"    ]. Alternative agents for the treatment of ischemia, arrhythmias, or hypertension that do not carry the risk of bronchoconstriction can also be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    When initiating a selective beta-blocker in a patient with COPD, careful guidance should be given regarding new symptoms (eg, dyspnea, exercise intolerance, cough) or changes in medication use patterns (eg, increased need for a beta-agonist inhaler) that would prompt reevaluation.",
"   </p>",
"   <p>",
"    The role of beta-blockers in patients with acute myocardial infarction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H7#H7\">",
"     \"Beta blockers in the management of acute coronary syndrome\", section on 'COPD/asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97494869\">",
"    <span class=\"h2\">",
"     Effects of beta-blockers on mortality and COPD exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In terms of overall survival and frequency of COPD exacerbations, there is some evidence that beta-blocker therapy may have a protective effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational cohort study of 2230 COPD patients, the use of beta blockers was associated with lower hazard ratios for both mortality (HR 0.68, 95% CI 0.56-0.83) and exacerbations of COPD (HR 0.71, 95% CI 0.60-0.83) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients admitted to the hospital with an acute exacerbation of COPD, use of beta-blockers is associated with reduced mortality. In an observational study, in which 142 out of 825 patients (17 percent) received beta-blocker therapy, beta blocker therapy was associated with reduced mortality (OR 0.39, 95% CI 0.14-0.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1205 patients with COPD who underwent vascular surgery, use of beta blocking agents was associated with lower thirty-day mortality (OR 0.37, 95% CI 0.19&ndash;0.72) and long-term mortality (HR 0.73, 95% CI 0.60&ndash;0.88) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort study of patients with ischemic heart disease hospitalized with a COPD exacerbation, treatment with a beta-blocker in the first two hospital days did not increase mortality, length of stay, or the likelihood of late mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97494824\">",
"    <span class=\"h2\">",
"     Effect of cardioselective beta blockers on lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;While nonselective beta blockade can precipitate bronchospasm in those who are predisposed, selective beta-1 blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) are generally safe in patients with COPD, even when there is a bronchospastic component [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/44,45,49-54\">",
"     44,45,49-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of cardioselective beta-blockers was assessed in a meta-analysis of randomized trials in which single-dose or long-term cardioselective beta blockers were administered to nearly 400 patients with either asthma or COPD and reversible bronchoconstriction (&gt;15 percent improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    following bronchodilator treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/55\">",
"     55",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single-dose use was associated with an 8 percent decrease in FEV",
"      <sub>",
"       1",
"      </sub>",
"      , but a 5 to 9 percent increase in bronchodilator response",
"     </li>",
"     <li>",
"      Sustained use was not associated with a significant change in baseline FEV",
"      <sub>",
"       1",
"      </sub>",
"     </li>",
"     <li>",
"      Long-term therapy did not increase respiratory symptoms or the use of inhaled beta agonists",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    inhalation challenge in patients with COPD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    caused a reduction in FEV",
"    <sub>",
"     1",
"    </sub>",
"    and in the bronchodilating effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    in addition to an increase in airway hyperresponsiveness to methacholine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/56\">",
"     56",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    did not affect FEV",
"    <sub>",
"     1",
"    </sub>",
"    or responsiveness to formoterol, but did increase airway hyperresponsiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97494884\">",
"    <span class=\"h2\">",
"     Effect of combination beta and alpha blockers on lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined beta and alpha blockers are sometimes indicated for patients with CAD and heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30679?source=see_link&amp;anchor=H15#H15\">",
"     \"Beta blockers in the management of stable angina pectoris\", section on 'Agents with alpha blocking activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data regarding the effects of combined beta and alpha adrenergic blockade (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ) in patients with COPD are limited, but include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      (nonselective beta-blocker with alpha antagonism) on lung function was compared with the selective beta-blockers",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      in 35 patients with COPD and heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/58\">",
"       58",
"      </a>",
"      ]. FEV",
"      <sub>",
"       1",
"      </sub>",
"      was lowest with carvedilol and highest with bisoprolol (carvedilol 1.85 [95% CI, 1.67-2.03]; metoprolol 1.94 [95% CI, 1.73-2.14]; bisoprolol 2.0 [95% CI, 1.79-2.22]), although the six-minute walk distance was not different.",
"     </li>",
"     <li>",
"      In a small series of 11 patients with COPD and hypertension,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      (nonselective beta-blocker with alpha antagonism) up to 1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      caused no significant changes in FEV",
"      <sub>",
"       1",
"      </sub>",
"      or forced expiratory flow (FEF 25 to 75) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/59\">",
"       59",
"      </a>",
"      ]. Likewise, in a report of 14 patients with COPD treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      25 mg PO twice daily for heart failure, no changes were noted in FEV",
"      <sub>",
"       1",
"      </sub>",
"      , vital capacity, or peak oxygen consumption with exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Celiprolol, a selective beta-1 blocker with mild beta-2 and alpha-2 agonist properties (not available in the United States), did not result in increased pulmonary symptoms, a decrease in FEV",
"      <sub>",
"       1",
"      </sub>",
"      , or increased airway hyperresponsiveness to methacholine when given to four patients with mild-to-moderate COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/56\">",
"       56",
"      </a>",
"      ]. In the same study, FEV",
"      <sub>",
"       1",
"      </sub>",
"      was significantly lower after four days of propranolol, compared with metoprolol or placebo, and the bronchodilator response to formoterol was blunted after propranolol, but not metoprolol, celiprolol, or placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is needed to clarify the role of combined alpha and beta blockers in the management of CVD in patients with COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Revascularization in patients with severe COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of severe COPD affects decision-making in patients with possible indications for coronary artery bypass grafting (CABG), because of excess postoperative morbidity and mortality in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. Expected post-CABG mortality ranges from 2 to 4 percent for all patients and is about 1 percent for those at lowest risk. Among 11,217 patients who underwent CABG, increasing severity of COPD based on impairment in FEV",
"    <sub>",
"     1",
"    </sub>",
"    correlated with an increasing frequency of postoperative complications and severe COPD was associated with early mortality, adjusted OR 2.31 (95% CI 1.23-4.36) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/64\">",
"     64",
"    </a>",
"    ]. One series of 191 patients undergoing CABG identified age &gt;75 and therapy with oral glucocorticoids as independent risk factors for mortality in patients with COPD; the mortality rate reached 50 percent when both risk factors were present [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/65\">",
"     65",
"    </a>",
"    ]. Postoperative arrhythmia is often the proximate cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/66\">",
"     66",
"    </a>",
"    ]. In contrast to patients with severe COPD, post-CABG mortality for patients with mild or moderate COPD is similar to the rate among those without COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/65,67,68\">",
"     65,67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with COPD who undergo CABG are also at increased risk of perioperative morbidity, particularly pulmonary complications that result from sternotomy and use of cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/62,63,66\">",
"     62,63,66",
"    </a>",
"    ]. Patients with significant COPD who survive the early postoperative period after CABG appear to have improved quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who require CABG, preoperative and postoperative optimization of pulmonary function and careful monitoring for rhythm disturbances seem advisable. If available, minimally invasive CABG may represent a useful therapeutic option, although it has not been specifically assessed in patients with COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=see_link&amp;anchor=H11#H11\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with CVD and COPD, percutaneous coronary interventions (eg, balloon angioplasty or stent placement) are associated with an increased mortality and rates of repeat revascularization within one year compared with patients without COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/30/17898/abstract/9\">",
"     9",
"    </a>",
"    ]. Using the National Heart, Lung, and Blood Institute Dynamic Registry, the outcomes following percutaneous coronary interventions were compared in patients with (860) or without (10,048) COPD. Patients with COPD had a significantly increased risk of death (hazard ratio 1.30, 95% CI 1.01-1.67). Of note, patients with COPD were also significantly less likely to be prescribed beta-blockers at discharge.",
"   </p>",
"   <p>",
"    Although outcomes after PCI or CABG have not been directly compared in patients with COPD, PCI is a reasonable alternative for some patients who would otherwise receive a recommendation for CABG. We suggest that the decision to choose one revascularization therapy be made after the patient has been fully informed of the relative benefits and risks of each approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12892306\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD) share tobacco abuse as a risk factor and commonly coexist. The presence of either disease can adversely affect outcomes of the other. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'COPD/CVD relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with concomitant severe COPD and CAD, a number of nonpharmacologic therapies (eg, smoking cessation, pulmonary rehabilitation, vaccination against influenza and pneumococcus, supplemental oxygen) are indicated to reduce symptoms, improve quality of life, and prevent exacerbations, as in patients with COPD alone. (See",
"      <a class=\"local\" href=\"#H12892415\">",
"       'Nonpharmacologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the pharmacologic management of comorbid COPD and CVD follows the same guidelines as for patients without comorbid disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of COPD in patients with CVD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H81297784\">",
"       'Treatment of CVD in patients with COPD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with COPD and CAD, we recommend that a short-acting bronchodilator be prescribed for use as-needed for relief of acute symptoms of COPD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients not on a long-acting anticholinergic agent, we suggest using a combination short-acting beta agonist PLUS a short-acting anticholinergic, rather than either alone, to achieve greater improvement in COPD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients on a long-acting anticholinergic agent, a short-acting beta agonist is used for quick relief of COPD symptoms. (See",
"      <a class=\"local\" href=\"#H27291990\">",
"       'Short-acting beta agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H81300262\">",
"       'Inhaled anticholinergic medications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of stable chronic obstructive pulmonary disease\", section on 'Short-acting bronchodilators'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concern has been raised regarding possible adverse cardiovascular effects of the inhaled long-acting beta agonists and also the long-acting anticholinergic medications, although the data is largely reassuring. For patients with concomitant COPD and CVD, we advise following guideline based therapy for COPD; most patients with severe COPD require combination therapy with both agents. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of COPD in patients with CVD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of stable chronic obstructive pulmonary disease\", section on 'Long-acting bronchodilators'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of combination long-acting beta agonist-glucocorticoid inhalers does not adversely affect mortality in COPD, although data are limited regarding specific effects on cardiovascular outcomes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Combination inhaled bronchodilator plus glucocorticoid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe COPD and comorbid CVD, we recommend using a cardioselective beta blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ), rather than a nonselective beta-blocker (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For those patients who also have heart failure, use of a combined beta and alpha blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      ) appears to have minimal adverse effect on COPD, although data are limited. (See",
"      <a class=\"local\" href=\"#H97494824\">",
"       'Effect of cardioselective beta blockers on lung function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H97494884\">",
"       'Effect of combination beta and alpha blockers on lung function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initiation of beta-blocker therapy, patients are given careful guidance regarding new symptoms (eg, dyspnea, exercise intolerance, cough) or increased need for a beta-agonist inhaler that should prompt reevaluation. (See",
"      <a class=\"local\" href=\"#H81297784\">",
"       'Treatment of CVD in patients with COPD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe COPD who meet cardiovascular criteria for coronary artery bypass grafting (CABG), percutaneous coronary intervention is often preferred if there is a reasonable likelihood of success. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Revascularization in patients with severe COPD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those who require CABG, preoperative optimization of pulmonary function and careful monitoring for cardiac arrhythmias are advised. A minimally invasive surgical approach may be advisable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=see_link&amp;anchor=H1036579116#H1036579116\">",
"       \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\", section on 'Patient selection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/1\">",
"      Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/2\">",
"      Reed RM, Eberlein M, Girgis RE, et al. Coronary Artery Disease Is Under-diagnosed and Under-treated in Advanced Lung Disease. Am J Med 2012; 125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/3\">",
"      Enriquez JR, de Lemos JA, Parikh SV, et al. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. Am Heart J 2013; 165:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/4\">",
"      Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/5\">",
"      McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/6\">",
"      Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/7\">",
"      Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol 2010; 106:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/8\">",
"      Konecny T, Somers K, Orban M, et al. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest 2010; 138:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/9\">",
"      Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest 2011; 140:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/10\">",
"      Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/11\">",
"      McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/12\">",
"      S&oslash;yseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013; 99:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/13\">",
"      Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/14\">",
"      Reid WD, Yamabayashi C, Goodridge D, et al. Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews. Int J Chron Obstruct Pulmon Dis 2012; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/15\">",
"      Entwistle MD, Sommerville D, Tandon AP, Jones JG. Effect of hypoxaemia on the resting electrocardiogram (ECG) in patients with cardiac ischaemia. Ann Acad Med Singapore 1994; 23:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/16\">",
"      Gill NP, Wright B, Reilly CS. Relationship between hypoxaemic and cardiac ischaemic events in the perioperative period. Br J Anaesth 1992; 68:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/17\">",
"      Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988; 94:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/18\">",
"      Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/19\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/20\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/21\">",
"      Petty TL. Supportive therapy in COPD. Chest 1998; 113:256S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/22\">",
"      Cason BA, Wisneski JA, Neese RA, et al. Effects of high arterial oxygen tension on function, blood flow distribution, and metabolism in ischemic myocardium. Circulation 1992; 85:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/23\">",
"      Sassoon CS, Hassell KT, Mahutte CK. Hyperoxic-induced hypercapnia in stable chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 135:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/24\">",
"      Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 122:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/25\">",
"      Schmidt, GA, Hall, JB. Oxygen therapy and hypoxic drive to breathe: Is there danger in the patient with COPD?. Intensive Crit Care Dig 1989; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/26\">",
"      Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/27\">",
"      Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/28\">",
"      Hilleman DE, Malesker MA, Morrow LE, Schuller D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis 2009; 4:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/29\">",
"      Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7:CD009285.",
"     </a>",
"    </li>",
"    <li>",
"     5.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD). www.goldcopd.org (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/31\">",
"      Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/32\">",
"      Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/33\">",
"      Tranfa CM, Pelaia G, Grembiale RD, et al. Short-term cardiovascular effects of salmeterol. Chest 1998; 113:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/34\">",
"      Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/35\">",
"      Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/36\">",
"      Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003; 123:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/37\">",
"      Bermingham M, O'Callaghan E, Dawkins I, et al. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 2011; 13:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/38\">",
"      Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/39\">",
"      Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/40\">",
"      de Mey C, Nassr N, Lahu G. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol 2011; 11:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/41\">",
"      Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990; 98:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/42\">",
"      Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991; 99:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/43\">",
"      Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/44\">",
"      Foresi A, Cavigioli G, Signorelli G, et al. Is the use of beta-blockers in COPD still an unresolved dilemma? Respiration 2010; 80:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/45\">",
"      Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/46\">",
"      Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/47\">",
"      van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/48\">",
"      Stefan MS, Rothberg MB, Priya A, et al. Association between &beta;-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012; 67:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/49\">",
"      Au DH, Bryson CL, Fan VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004; 117:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/50\">",
"      Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/51\">",
"      Fogari R, Zoppi A, Tettamanti F, et al. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990; 4:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/52\">",
"      Chazan R. [Atenolol in the treatment of patients with airway obstruction]. Pol Merkur Lekarski 1998; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/53\">",
"      Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD003566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/54\">",
"      Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/55\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/56\">",
"      van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005; 127:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/57\">",
"      Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/58\">",
"      Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/59\">",
"      George RB, Manocha K, Burford JG, et al. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest 1983; 83:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/60\">",
"      Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999; 138:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/61\">",
"      Gao D, Grunwald GK, Rumsfeld JS, et al. Variation in mortality risk factors with time after coronary artery bypass graft operation. Ann Thorac Surg 2003; 75:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/62\">",
"      Islamoglu F, Reyhanoglu H, Berber O, et al. Predictors of outcome after coronary artery bypass grafting in patients older than 75 years of age. Med Sci Monit 2003; 9:CR369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/63\">",
"      Medalion B, Katz MG, Cohen AJ, et al. Long-term beneficial effect of coronary artery bypass grafting in patients with COPD. Chest 2004; 125:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/64\">",
"      Saleh HZ, Mohan K, Shaw M, et al. Impact of chronic obstructive pulmonary disease severity on surgical outcomes in patients undergoing non-emergent coronary artery bypass grafting. Eur J Cardiothorac Surg 2012; 42:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/65\">",
"      Samuels LE, Kaufman MS, Morris RJ, et al. Coronary artery bypass grafting in patients with COPD. Chest 1998; 113:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/66\">",
"      Cohen A, Katz M, Katz R, et al. Chronic obstructive pulmonary disease in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1995; 109:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/67\">",
"      Michalopoulos A, Geroulanos S, Papadimitriou L, et al. Mild or moderate chronic obstructive pulmonary disease risk in elective coronary artery bypass grafting surgery. World J Surg 2001; 25:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/30/17898/abstract/68\">",
"      Fuster RG, Argudo JA, Albarova OG, et al. Prognostic value of chronic obstructive pulmonary disease in coronary artery bypass grafting. Eur J Cardiothorac Surg 2006; 29:202.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1437 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17898=[""].join("\n");
var outline_f17_30_17898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12892306\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COPD/CVD RELATIONSHIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104140482\">",
"      Coexistence of COPD and CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104140467\">",
"      Impact of co-morbid disease on outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104142942\">",
"      EVALUATION AND DIAGNOSIS OF CHD IN PATIENTS WITH COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12892415\">",
"      NONPHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12892425\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12892461\">",
"      Cardiopulmonary rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12892433\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12892613\">",
"      Management of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Effect of hypoxemia on the heart",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Indications for supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4096341\">",
"      Noninvasive positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT OF COPD IN PATIENTS WITH CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81300262\">",
"      Inhaled anticholinergic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4096480\">",
"      Beta-2 agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27291990\">",
"      - Short-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27291983\">",
"      - Long-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Combination inhaled bronchodilator plus glucocorticoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81298178\">",
"      Roflumilast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81297784\">",
"      TREATMENT OF CVD IN PATIENTS WITH COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97494869\">",
"      Effects of beta-blockers on mortality and COPD exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97494824\">",
"      Effect of cardioselective beta blockers on lung function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97494884\">",
"      Effect of combination beta and alpha blockers on lung function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Revascularization in patients with severe COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12892306\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1437\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1437|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/28/35275\" title=\"table 1\">",
"      Severity of airflow limitation in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/21/8538?source=related_link\">",
"      Arrhythmias in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30679?source=related_link\">",
"      Beta blockers in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17705?source=related_link\">",
"      Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/23/30073?source=related_link\">",
"      Cardiovascular effects of nicotine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=related_link\">",
"      Dobutamine stress radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=related_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=related_link\">",
"      Pharmacotherapy for smoking cessation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=related_link\">",
"      Role of anticholinergic therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=related_link\">",
"      Role of methylxanthines in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_30_17899="Histopathology report melanoma";
var content_f17_30_17899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathology report of melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Essential data",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diagnosis: Malignant melanoma, in situ or invasive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Breslow thickness: mm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ulceration: present or absent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mitoses: number/mm",
"       <sup>",
"        2",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Microscopic satellites: Present or absent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vascular invasion: Present or absent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Surgical margins: Adequacy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other prognostic data",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clark Level: I, II, III, IV, V",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Growth phase: Radial or vertical",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Regression: Present or absent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TIL's: Present (brisk or non-brisk) or absent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histologic type: eg, Superficial spreading, desmoplastic",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Roy King, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17899=[""].join("\n");
var outline_f17_30_17899=null;
var title_f17_30_17900="BMT infections and environment";
var content_f17_30_17900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Environmental exposures causing potential infections among stem cell transplant recipients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family members",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recreational activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swimming (water-related pathogens - see",
"below)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Outdoor activities (Lyme disease,",
"relapsing fever, Rocky Mountain spotted fever, histoplasmosis,",
"ehrlichiosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Food and water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Water-related pathogens (eg,",
"Legionella pneumophila, Pseudomonas spp., Acinetobacter spp., atypical",
"mycobacteria, Aspergillus spp.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Food-related pathogens",
"(Staphylococci, Escherichia coli, Shigella spp., Salmonella spp.,",
"Campylobacter jejuni, Clostridium spp., Listeria monocytogenes,",
"Entamoeba histolytica)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Travel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bacterial:",
"        </strong>",
"        travelers' diarrhea (E. coli, Shigella spp.,",
"Salmonella spp., C. jejuni, Yersinia enterocolitica,",
"Clostridium difficile, Aeromonas hydrophila, Vibrio cholera, Plesiomonas",
"shigelloides), brucellosis, Mycobacterium tuberculosis, relapsing fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Viral:",
"        </strong>",
"        traveler's diarrhea (eg, rotavirus, adenovirus, Dengue virus), hepatitis A and B,&nbsp;HIV infection, yellow fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Parasitic:",
"        </strong>",
"        travelers' diarrhea (eg, Giardia",
"intestinalis, Cryptosporidium parvum, Microsporidia intestinalis,",
"Strongyloides, E. histolytica, Cyclospora cayetanensis), schistosomiasis, malaria, leishmaniasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal cages and reptiles (salmonellosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bird cages (psittacosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cats (bartonellosis, toxoplasmosis, cat-scratch disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cats and dogs (Lyme disease, salmonellosis,",
"campylobacter infection, cryptosporidiosis, giardiasis, Q fever)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rodents (rat-bite fever, brucellosis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17900=[""].join("\n");
var outline_f17_30_17900=null;
var title_f17_30_17901="Sites of Pasteurella infection";
var content_f17_30_17901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of infections caused by Pasteurella multocida",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ infected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific infections",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common Pasteurella exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin and soft tissue",
"       </td>",
"       <td>",
"        <p>",
"         Cellulitis",
"        </p>",
"        <p>",
"         Lymphangitis",
"        </p>",
"        <p>",
"         Subcutaneous abscess",
"        </p>",
"        <p>",
"         Infected decubitus or stasis ulcer",
"        </p>",
"        <p>",
"         Breast implant infection",
"        </p>",
"        <p>",
"         Surgical wound infection",
"        </p>",
"        <p>",
"         Necrotizing fasciitis",
"        </p>",
"        <p>",
"         Psoas abscess",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cat bite, scratch, or lick",
"        </p>",
"        <p>",
"         Dog bite or lick",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone or joint",
"       </td>",
"       <td>",
"        <p>",
"         Septic arthritis",
"        </p>",
"        <p>",
"         Osteomyelitis",
"        </p>",
"        <p>",
"         Septic arthritis with osteomyelitis",
"        </p>",
"        <p>",
"         Septic arthritis of knee or hip arthroplasty",
"        </p>",
"        <p>",
"         Bursitis",
"        </p>",
"        <p>",
"         Tenosynovitis",
"        </p>",
"        <p>",
"         Dental follicle",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penetrating animal bite",
"        </p>",
"        <p>",
"         Distal bite or scratch in setting of abnormal joint",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory tract",
"       </td>",
"       <td>",
"        <p>",
"         Pharyngitis, sinusitis, epiglottitis",
"        </p>",
"        <p>",
"         Tonsillitis, peritonsillar abscess",
"        </p>",
"        <p>",
"         Otitis media, mastoiditis",
"        </p>",
"        <p>",
"         Submandibular abscess",
"        </p>",
"        <p>",
"         Tracheobronchitis",
"        </p>",
"        <p>",
"         Pneumonia, lung abscess",
"        </p>",
"        <p>",
"         Empyema",
"        </p>",
"        <p>",
"         Glossitis, uvulitis",
"        </p>",
"       </td>",
"       <td>",
"        Non-bite animal exposure or no known exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular system",
"       </td>",
"       <td>",
"        <p>",
"         Bacteremia, puerperal sepsis",
"        </p>",
"        <p>",
"         Endocarditis (native and prosthetic valves)",
"        </p>",
"        <p>",
"         Purulent pericarditis",
"        </p>",
"        <p>",
"         Mycotic aneurysm",
"        </p>",
"        <p>",
"         Infected vascular graft",
"        </p>",
"       </td>",
"       <td>",
"        Non-bite animal exposure or direct contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        <p>",
"         Meningitis",
"        </p>",
"        <p>",
"         Brain abscess",
"        </p>",
"        <p>",
"         Subdural empyema",
"        </p>",
"        <p>",
"         Epidural abscess",
"        </p>",
"       </td>",
"       <td>",
"        Penetrating bite, direct contact, or non-bite exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal tract",
"       </td>",
"       <td>",
"        <p>",
"         Spontaneous bacterial peritonitis",
"        </p>",
"        <p>",
"         Omental or appendiceal abscess",
"        </p>",
"        <p>",
"         Peritonitis due to ruptured viscus",
"        </p>",
"        <p>",
"         Liver abscess",
"        </p>",
"        <p>",
"         Gastroenteritis",
"        </p>",
"        <p>",
"         Granulomatous hepatitis",
"        </p>",
"        <p>",
"         Peritonial dialysis-associated peritonitis",
"        </p>",
"       </td>",
"       <td>",
"        Non-bite animal exposure or no known contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary tract",
"       </td>",
"       <td>",
"        <p>",
"         Cystitis or pyelonephritis",
"        </p>",
"        <p>",
"         Infected ileal loop",
"        </p>",
"        <p>",
"         Renal abscess",
"        </p>",
"        <p>",
"         Vaginitis, cervicitis",
"        </p>",
"        <p>",
"         Bartholin gland abscess",
"        </p>",
"        <p>",
"         Chorioamnionitis",
"        </p>",
"        <p>",
"         Epididymitis",
"        </p>",
"        <p>",
"         Tuboovarian abscess",
"        </p>",
"        <p>",
"         IUD-associated endometritis",
"        </p>",
"       </td>",
"       <td>",
"        Non-bite animal exposure or no known contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes",
"       </td>",
"       <td>",
"        <p>",
"         Conjunctivitis",
"        </p>",
"        <p>",
"         Corneal ulcer",
"        </p>",
"        <p>",
"         Endophthalmitis",
"        </p>",
"       </td>",
"       <td>",
"        Direct contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        Supportative thyroiditis",
"       </td>",
"       <td>",
"        Cat scratch",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Weber D, Wolfson JS, Swartz MN, Hooper DC. Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine 1984; 63:133.",
"      <br>",
"       Klein NC, Cunha BA. Pasteurella multocida pneumonia. Semin Respir Infect 1997; 12:54.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17901=[""].join("\n");
var outline_f17_30_17901=null;
var title_f17_30_17902="Adenylyl cyclase";
var content_f17_30_17902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenylyl cyclase",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 399px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the adenylyl cyclase cyclic AMP system. Activation begins when a stimulatory hormone (Hs) combines with its receptor (Rs). The hormone-receptor complex interacts with the stimulatory regulatory protein Gs, allowing it to take up guanosine trisphosphate (GTP). This activated form of Gs then stimulates adenylyl cyclase. This step is followed sequentially by the formation of cyclic AMP, activation of a protein kinase, phosphorylation of cell proteins, and the physiologic effects of the hormone. Other hormones (Hi) inhibit adenylyl cyclase by binding to their receptor (Ri) and then activating an inhibitory regulatory protein (Gi). (Redrawn from Rose BD, Clinical Physiology of Acid-Base and Electrolyte Disorders, 4th ed, McGraw-Hill, New York, 1994.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17902=[""].join("\n");
var outline_f17_30_17902=null;
var title_f17_30_17903="Skin changes post transplant";
var content_f17_30_17903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sclerodermatoid changes after bone marrow transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 263px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEHAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5pt7YmNTg9BmriWfOAMkdeOlaFvCEiA74qzb2/UgcVxyqnqRpGaLUenFO+y7jgce2K2FtuganG22PjA/Os/amqpGPHYqGO4cU82ER+8ik98rWzHbhu3SpRbru5UY9an2oOkc62mwEj9yuO5AqBtPh+0BFgyv97tXV/ZsqMLkVEbfdJwCBmmqzE6C7HOHR7dgcIwb68VG2jQN9zePUZ5rq2tgwGV5x60rWIIBJwQOMUe3a6k+wi+hyH9hx44kk/IUw6GMEpMePVa7RLQgneFI9qbJY7GXAOG44p/WJdyfq0Oxw7aNICQJV/I006LcDo0f513DWAbrkHHWiKy3Kcj2wRzVfWWL6rE4ZtGu1PCqfoajOlXijPk5HsRXoJsyq5ZRj0posgQSAQDwfahYpk/VInnhsLr/n3kP0XNMe2nQ4aGUH3Q16H9hK5PXtxTGsyxOFwSOhqlihPCLozzsow6qR+FNIr0A2YZiNvsenFQmzRsEorHuMVSxK7EvCPucLRiuybS4mbBiXn26VA2jxhsPEvNWsREh4WXc5THtQRXTyaJDtzsIx74qL+xIiOTIp+tNVokvDzRzmKMVtNo4APztgd6Y2kNs3Bzj6VftIkOjLsY9FaL6ZIq5Vgw+nSoWspAeSKakmT7OXYqUcVYa1lHbP41G0Tr1U07kuLXQiop20+lJg0yRKKXFFACUUUUAFFFL2oASiiigAooooAKKKKACiiigAooooAKKKKAPQ4YA0eMcH1q1a25WPbgcfrU0cLBeMEEdKtwR9SOnoa8aUz6FIgWHC5PWnvbhk7ZFXI4wW3dTjpTp7YSRFPmBPQis+YtIqRQYxuGVFTJFuZhjIq8luQqgnoMcd6kigwDtxz+lS5hYz0gAU8fgKYbbaflH4ela3kll6dKVIi64IAFLnEZiQKSNwHoake3ORgADNaAgAPGB9BUscR2j5Rj370OZK0MxbYHkDJHepRACOeOOnY1o+TwMdKcsW35evGRxUuYWuZL2o7ZweScUkVoMuQckkYA7VtCHeu7uR1pPI2sOnrRzgZotwOXHB9qha3VeAP8K1mTavGdp5zR9nyQehA9KOcFExxbEn7vIpPs4B+7379q21t8cAdOaXyd6nA9qPaBYwJrUDnAKj9arvZjLDaBx+VdC1ucA/L9PSomgDgZXgdaaqBYwY7U4IbBGKa9ryflFbrQ4/hx1H4etRm3+XJXBq1UFyoxJ7RSGA+6BwR1quLX5QTkg8Yx1rf8j2JPt6VC8BwPY1SqE8phvZr1IBJ6g1VktNp2EAe3+FdF5IyrDHPUEYqKa23sF49Ae9aKoQ4I5ia0KK24YX2qtLZMQQp56ge1dQ8DHpg+3rVSW324fow5rWNUzlTOXa1O3DDp3xVZrbOVA57107QgK2cHnHSqskPAwPmzgmtVVMnTOZltsZGOarNAccjFdS1uGLDqF7EYqlcWoQc5x1xito1TOVM58xMDjFRlT0rXkgGTjr6EVVlh5PrWqncxlS7FHFJirDQmomQjtV3MnFojop2KSgkSkp1JQAlLiiigQYpKKKACiiigAopaO1ACUUUtAHsawgqMAfhUiKw5C5pLZt3PUEdavRor85yw/CvAcrH0ijbcbHFhx3z04q1HDyTzuHA9qWBPnOehq7DFg89+lYykBBHbnA+UfSpIoSXPyjPp61fWIKMY5+tSxw/eOOT19qjmJbKPkDqRgZ70htyc7cc1e8v+EEhQPxpCnlsshyQex7UuYEUlt9pyO/OO9SiH5j8pC1eEIJzjipFiyM9MfrRzAzOFuN2RnHvQIRuzWmIuDjv2qMW43lwMM3I/CjmEUzGcHPbsKVYsnpz61ckiO1vl5pUjPcfiaTYLYpeRuyMdTmnCEACtIQ8jjnFRzRdmH1NK7BO5ktu87y9pI7n0qwsbAg4+XHzD+VXGhB2nbk09I8NnqRwaVynYz5Yh/CM5wQRULw7ACBntzWsYl5wPY4qN4QQFI5z2pqRNzMaAYyOcc4NRvFt4IyMda1RFgYAzzn3pXiXaSfv+lUmJ6GA8J9/TB4xUEsAJXkcc5ramg5JI4I4xVYwZYhRjHbFWpFGKYTvJkLNu5YGmPGT0GD0ya2XhUjBBwRwarNDn5XU+3tWikSzFljI7DBqKWMZ6YIPTvW09vhT8p4/nVX7MXfPOD36VopktXMWWHIKgY5546VWkg5+cAoeCBW6bdtxI57ZpJLUlflAAz0NaKoS0czJA24A5PYHv8AjTfs+5SDnPXP+FdDLZHZyOvIwehqubIg4K4I5HFWqhDicvNbAO27k9QR3qpLbKwPGB7V1U9k5hJxhhzVH7JKoOQMkdq2jVM5UnujnHtGUYAwM5BPaqstqWJKrkY59q617IEE9CeDz1qlJZnawx7GtY1TKVM5KSEr2xURTFdDc2YBKqMgHrVSWxZQSBW6qIxlSMcqaaRV2aAqelV2QitE7mMoNEVJUhHtTcUybDaSnGigQU2looEFFFJQAtFJS0AeuQSMgAGM9APatS2Y7d2CffrVMwq10pVW5GMCtqzgXyeVGcdq+dmz6t2sS2myTJAIHHX1rViUDBXkVWsog2VI+UitO3hCj5cL2rnbuYVGkxYYQSOQCc8elT+WARnrjvU8SDJHrxSiPJIHFSYuWpUki6HaPXNKYW56MPcVbKkrtAyPSnLHxnqaA5ymseOpGB2qYAccD196k8nD5HHtQkZ2+gHQUrlNpjCvAwBz+lO2kjIHT9akUEjpk98jpSg/Nn0GM0EkRQHB45OKeIxtA25+vennIxjGO+akydoAPvTZOpEVAyOKjkAGSRz2BqaUsMZ6e1NVQdueOKTZSXUhX0bimuCMjg5qZYyc/wAqkMS7QTzUlaFTbk59PX1pq8k5HXnjtVllVQfSmMAPWmncCFkAfG38qaUOf93g+9WeGIPcjHPFIi/LwB7VQrlRowR09jiofIA4BBrSZMc4/KmPHxggk9jTTFczJIQOOlQyQ4I4OenNaskRIXAAHpUckeSp5xnBGKfNYaVzONvgkkCoZbQZOMYNbQh6cfT3oMCjPYU1MNjBFovccn8aa1nkfdAz3Nb7QADjnd1qGWLbwF4NNTFuYUlmAevFV3thuUn5RjGT0roGgDAhulQS2gPGD+P8qtVBWOdkgA5KjHTGKpy2p3KydB1rqXth6ZxxVea2AyApyOTirVQLHMy254yF59etVZbY4PTiulltA2RgeoqBrcKvQHsa1VQlpHJzWmQWKglv7oqlPZjnjpXXz2mOCOD04qpLaq4JJz7CtY1SXTTOJubIsM8cd6oXFgwHyp9Ce9dxdWbYII3Z9uazp7HG7g5PU10QrGUqRxMto6E7sYqBocV1k1hg8r14NUZrPg7Vxj1FdEa1zCVHyOdZCKaQfStd7BgCduT+lVJLVlyCuPetVNMxdJ9Clikqw8WDxkfUVGy+gq7mbi0R0lPKkdQRTcUE2EoFKaPxoA+gBZAnrjHQjrVq3iMUZG7rxnFDqwcf3T71agUMuCMn1r5du59Ld21JrOHag4J960Io+Bu4zUVqMKoxx71fiXkjGf6Vm2YzYRr8uGAFShNpw2M9aVcEnqf60HlgRxjtQY6jduTu7HjFPUDaBj5abk9On+NJGd2eeaB2uPC/KcDPNKoAOGO0+pqRSSTnoKcuOTgGkK4wxhgQMemaaI8sOO1SNlRnt3wKXIdMgc9RTsCbIiu7Occ8DFKkW07jnOMdaeDliw6VIvIGRwexpDbZEyARnIyfSk8v5vp+tSsMHAJ4pQRjpgGhgmQ4AyM8iopWCx8Zqw4AbIxnH51TkYKxU5+gpFx1BRwdw49KglYBWyOvT2qwD3PTPSoWjViN3DCkUiIHPByQKsp2B4BqukDq65IODU6rufA4OeKdxtDpNqMAQQDTgoZSBnHY1LszywGaeigAdOe9FyNEVRb4J3E/nTjCvAA5FWcYBzyB14pi/K0hbAHrnoMUh3ZAqFDtHrx3pRFxgZOeuakUHeS+Cc/LjjFKQWBA6njP+FMGQGM4AHY1FNGW5/8ArZq9t259qTywwOPxpkXM1oeMEZ/Ch4h6fT3rRWPIJIAwO1MdNuCR0707juZjxAnp1HSqnlEgh+fT2rXkUMoI/TtUBhVmbHNCZSMo24DdOtRNAp7d622h2qcAE1VlUDI/iHtWikxXuc5qenNcYWORk75BqMWwVdo5I4ya2zHnO4Dio5IN2CV71opA9rGG9qCgLKR7VUntueEz9a6F4ee/HNQPb9zitFNoSOYmsS/YKOp4qk+njktzniuuktcg4HX1qtLaZHTB6VoqrDlTOPmseoAx9Koy2ORnbkdOldlJZnnKEHsSOPwqvLYg4LAg+lbRrGcqaOGnsE7o2fTNUZbEg/KjD6jFd41kpDBCox69aoXViC2eSSa3jWMZUTiZbRx1Q+tV5Lcg8IR7E118tmCemW96pS2Qwc8+ma3jVMpUjl3ix2NM2+xrelsDgnAHpVKWzcP939a0VRMxdJ9D6FZFxyafAn8QA4quc4DL+BqzZMWJ3YU18yz2uho2o5LYFWQfbBFVYSOp6+1WOWBP61Bm9yT0bOKegwxyc57+lRRYYE4+tPb5BgYIz+NBPkOKnIC/jmk2qOehPT2pBnYvAJFDqSeTz7UIByMeOx96czgZAOOKbt+cHge3envGN3qPQ0xEccxIAPBHWpixK8Y55qEp8+OvtS7NuSPWlcqy6FhVO0c89aCDt67j6UkZJBGPy70/cD0HHXmggGOcAjvzzUVzkDgEjtg06UkZxjnmozhztAzgcUMI6AHJQEEntUciDIbbyKeMg5TuOamTaAAev86noabFI7lbOOMc05VEgA7E9utSypwcYIHalgVdnAPPelcvpcZ5eWOVzjgYqRVAUY6HjFWdo5II96jIIfp7Yppk3uB7ADOR+VJtwAaczhSMkc9CKYUORtYD0zSBDZGOMg8UKd2OB9aqu58wAnAPUVJG2EBJ4BpJmjhZDZSB14I6Gmw3CsByARwRmm3Q3jB4757YrLZGQ/McjNJyNI01Jam8shcgqOAcVMQVGRjkVQt5SkIbI/E1ajk3jOME9qtM55waJCuSN4x3696GTIwelORsrkYINLjrgUzMikQYIAFVfICnI6VcJ5x1NIUBPY5FAXaKZQ7R09KimiyrZHSr4jzyOBTGjz0GQapML2MgW4aTcfoAe1Oa3+Xr0PpWk0QB4AxjmmMnfimmNyuY0lsFJ71G1uOmPpWwyZ9BVeWMAj2q0wuZJtzjk0Nb4XnB/CtPyuSR34phiUDnmqTsK9zGlt8nOOKrNCCfmOCDnBrdaHB9zUDW+TnaPxFWpDOentQQcKPriqktqB1BHHOBXS/ZySd3LfpUUluSDxkAcVanYLnLTWKlchef1qlNZBScr+OK617dNxyCCBnOM1Smtic/xDPcVrGoS9Tj5rA7SQM85xWXdWoEvOeldrcQFQVJ5NYN/ARP2AI710QqEShdaHp2Bk8HHTFKhKMOxPY9cUsbK2MjkGpY+WOeGB6npXkPU64uxegyeegAqwpKcNyM9aqRv8zY6YzVuNt6nkH2z1qbGckPUbuQTnoRUoXA3HBI4piBR0Iz0xUkXJYEdP71BDEUqpPHfGaibKu569x71O4C8qMVFtySpOM9/WkNDoyXQFl2tjkEg05vmH3sEdPeq7FkcYxx29asxsGJBAC+3rQNq2oLnKk/iaSVC7cHg9ulOGDxzj3605e5OMikK/Uh+ZC3PFSbsjj5u/pSS8HoM9zTQwUggAdjTK3HHlBuzj1B6VEzGLgckevOalnSQwkQ7fNxwG6H2qtdcpkKSV/Q0MIK+gjTjIZWxzU3nDGV5NZ0sHzNggEYJXtVmGMsuM4wOmahtm/JGw9p8DeRyD09amgkBwR0I6DvVcoXVuPm64oUbAobgdzUpjcVbQviVRx1jPB9qTeAPlbI7Z9KqQbm3Bhj2qfCgAHkH0qjJxsP3CRcY5zkUjqCh68cfjUe4YGMipN+3OAOTxQO1iu0SyKNw5U8H3qXaE5PQ+/NDEFmwMetRyAhNxIB6VN7F7gxCoBwT7mmeQkknB601oyysEPXjmrNuqiEqeGFLcp+6tBsdsQSMZA6Cp4R3A6HnnpT+QuBinjAJIGM9famu5jJt7hjBPoRTC5xjHzf0pwXk9P8fekK59h61ZlYCpK5By2OKM8gevJpxGVXGMj0ppUY3KMMe/emIfjnOBTCOuBxSkDrkk0pIA6Y9aaJaIsZJGOnvTCuQR696kc5HXrTdo9STTQELx8885/Go2hBGSBzVphu49KiZQFx1FWiblPbngD8vSozGSeOnfmrDHaOacqgg4H4Uyr2KjJkYC1FIh7Yq+Vxxx1qJlBPOOO1NBcptHx82AfaoJIwD0zV+QdOM1XZAeOAfQU0wM6ROc57VUlhHPGa2Gj7VVmjHdQV/WqT1HcxJYeW3KcZ9c1k38JE4xHnK+uK6eSP+6PxrKvoT5wyFBxW0ZCubURbBDDBx1z1q4SxCMcfl1qCMHOBzgjHririMGAweAfSuJs6mOiBXoMnpnNXLbiXAAGe1MjQZ4U7cZJz+lTxqAwCjr0J60jOTLG4Kc5GB2FSIPmI6jrUIABbJ+WpIQVOCeBQZtaaDl3HeHYSZOVGzbtHp7/WkwMZPI607eCOvSmsQNvOcjHXrRuJKxBIjZ3Dke3enxkHI7jFT7FK8/dqocq3y9CSal6GifMiwW3JwQDnJIqPJPzADPcUqAjkYAPFPiXaCDyeh96ExbC7QevPHFAjBYHpnjpmnxoBnONw5Iz0/CjdxlcGkwXkOA28Ag1G8ZbOP8+9SqPmyTwaR8INw5PemCK01tlAQeR2p0UIWVT6joanRxzg9aazEsMrg5PftUuxopStYZIq4Cgc9qrypltrYHcHNTSHL5U5pCR/EAeOaCo6EceSo3ZwemRTpG2qcdaRzsPUEAflWbnyoRGruyIMDecn8TSLjG7LBc5JBz3zUiyHaGJxxzx0rOW4BBGCAOoNRyXpLrsPbp60WZr7O5rCcBstwuKnX94R3Fc+jfaVOQSOpxV23d4+ATgdO9DT6ilTtsaGNi4OR2pjSbWIIyDxShtwAY8U9MHhvwqSF5hDJuDJkZB6jvVkKwyN33eRUAVVIfAyTUokU7mH3sdKLkzXYcrZfqePapPL/ukY9Kro4KkDjvT1nKD5j3xVJoylB9B7AouRjimI74IYAe4PWnuQ6nB4NQFiFGeT6mqTISuWIyckk8dqeUBU5xzUEbbRyQx61MGyMnr1wKpESQ08HAGD3qMMdxBBGO9G4eYck0pIIGT1pisKAOtNYbgc9jSjjj9TS9uePeqIZAyZbpTCuO9TE8nimuOO1O4FfnoKj57DHfAqc8N2ApCACOcA9aoaZA2G6jpzUbKD2zzxUrAhunGaryA7hxnvxSKSEYcn+YqtLGABVkZ+YYPvUT5IB7mmtxNFKRDnJ6GsjUF/fjn+H1rdZST9Kyb9QZxkD7taJiRbs/NBwQygdCa0CNqZQHNJFHuTHpzn1NXIUwq8cY5rnZ1ymmKrZQOBtz9761NF8xG4jdj/ACajVCoYjp6U4A/wjaeoNSTYmJIbtgnnnrTwxXhs7ahYGRjxyOoxTuTER/dGM4oYrD1G7kDI6YqTZ8m0fUGqtm5DvGc4BzyatFsjOMHpSFJWdhxDEhemRn2pjKNmRjFTBiYsk8gdQOajK71Kg9DyaZKIpULgMCc8YwafEzcHGfWpAqqmM4OMUsahSzFt3oAO3pU26l3VrFc6faDVP7S8kC9aPy/O3NnbjpjO39M1Iindg8dDip8fuivr0qsxMb4JyPWlJt7jguw9QrXIl2/vQu0HP8JOSMdO1OlYAEHgN096rSsdw28Ed80/zVwTkdM0J3G4dUOZ1X7xx71FNLjJLHr270yYs4B3YUcZxUZgcjjOG7dM0rNmqSW5cjbADDn1qGYBCCCeeMUxMp6/LwQaS53Mm8E5z09aQ1GzIZJGVjjIBH1qKZfM3DJD9aYMbflJx79fpSTPmMEkfKOD0oubqNip5pEuHyig/eI6moZ1bcSv8K7h6YoeRJmKsCWPSoJJAf3cuCp6EdvatIo2UbGhYXkagoinee3YUtzKLaUN5paRsnZVJISitKJACRzgZIAqCBjIHdGJlI+/6D1x9apq5HLG9zZjuR8kinII78VZW8yu4D5SMVkmBpAoGeoz71ZKsJEC/dQ5xWWgOKNRblSgUE8dCacpfIBGAe46VXQAwbgAT1PFSJIZE2gfL6CszJq2xKUcSbgwU9KsKO3BwOfakRRjLdcUJnGSecVSMJO44DaMcnsBSBW3ZLc0wy7PvHHoaVHDBipPAxzTIaZLIBnGAR3pryEEc5FN3HcecZGBSTKGUYz+FaIzsOMox8hyTzT92GGDwe1UJh5MYfOSTgCiCVyvP5mq0Bw0uaBP9/k+lOU/L6Y6VTWUnr1HFP8AN6Z4HTmmZuPQnGPxprZK8VHvABwcHNPZwMcYNNIhoY3J+nbPSmEH0yvr3oWQbicYHejcCOMc1dwsNOOR1IHeoyPUdO9TFRg9ietRsB680hkZHPHXHFVnBAwOlWXGQQvWqz5Bw3J70LcCBgOOuazr1czcsBx6VquB+J61lX4dp8o5UYHAFWhG7EMLnGPr1FThuACAAPXvUMLMVJKg+tWlIZBkH2FYLU1YkYLAg/KwORUqAbWGOvaljC5Xjk/qKmYDCsRgjvSByK64EmGyGByMd6WRcuxOeakMYkQ4O1jTSm4LuJ344NJjTW5VEb8YHzKfvDuKuxDjLYzyBjuKGU4Ht39acp4DYxxg+9A5PmFjAGQBtzxT+Npx16EZprA7c8UqtjJYZGOtFyLX1EIyGGDj9SKaSMFgQRjjHNOOSykDIpirjhAAATwB1z1oZSFJwmck46e9V5UI+YZyTn2qYqnABG49AT1prhkGM/KfXtUM1iU1DzSYGSwz93uadJbTFxnj19qv2RABI4C+3en3UwLYIwxGR61aSsJ1Jc1kjPtpVjf96pOzkg9fqKstcxyN+6BK5yOaqyRiWXc/PpjrUccckJfy8Ek5qXKxqoKWvUkmdg27Y2MjkmopVV4wUJU5ycHoaikd3f8AfArzgY7mk2lRhgRuOPep31NVGyIXld3AKIuOue9NnjLpk5Ixge9K8SF8kncckD0qNJGCbpMHb90+lBpt8Jky3McD+Xt2qBx6g1DvSSFVlkVmPTH9ak1ICaVvLRiV5z2rJaORVG3qT69K3gk0b2W5qWUjp50fyjtj2qWOJVkGw7geuKwLm+bhXjKyAYDKa7DQrDZbl5BlmGee1FT3VdmU5cupGI33puJWNQCw75qyG2h25KZ9OQKlnjJ2xsG8wgDIFTWyFVaNh939a55SuLm0uJbYZBsYKSOgqaNW3MMAYOKaqFJh8gxjORU0al3BOM9wKm5lJlhVxyT0FNb5WwM4/rSksUyOoqG7uDb2pl2M+3rgc0zGzbsE0bSFeec857VIq9cgAiozh0VhkE/NjvTiSxHBA7+9UmJoeGAPJBPenOdygknj9KZ94cjJ9uMUOfLAYncp46dKpMzaI2QtLk42g+lDKFUgdR3NPDZVsdqidvkIY4B4HHNWg3GMRn73HU+lMJ+YAZz6nj6Uroyn5Btx6jNWrZ4JAPMTvgsB3pocmoq5ElvIq7i3y+o7UzzcKqlvnOSPcCtFgq/KMbW79jVINHFKYyAQevemmZc3MRktjKmnoxBxznFOuAuR5QGP50gUhT3A6VokS3oI5OAV5PYUNkk+v86QKev+RS9D1pITGklWJ5JNQzEAZqQna3cmoJgrBg4BU9R6009RWI2Xg5OfpWVfqDOOP4e1aDNtBGRWPfznz+naqQcrb0Oljj+YMDnPUiraIQArHOAOSeTUMJUgg8kdMVYOclujcZxWLNG9SWNRnoAOxqbB2nH3hzzUa45ViTu5yamI+UHGMDFIhjOWXKD5hzj1puMsCvrg+1SJwqsnH1pSN3IOG9RS33HsIRt+XPbIpsZJXB5Bp7nkAj5uv1o/hyvQHBFMLilOPUdxUKIVPHIA4zU6PuHHFIcbeeOeKllJvYRQNwI44xQAQuf8iomcF2zwc/rUm4BA2M80kOxFIoJGR34NK2GYd2HGT/KnPwOOcnOfShVAfnI9alI0voMKYjPlDAI6/wBKqSWz+Zy5yeK0MHB49+Kgl5blst3oZUJMSODy0VuOOCP604jJOOn0pAzK/HKe9Clhw4O71BqSrsrOqsWxGoI9qgjO0PuUkH36VbdSc9jnrUErOgzxjsaEaLVWK8zDaf3YBPTms6Z2RsNtAPG72qzPIq/NJlh2AHSopmhCFw3UA+tM3grFa6RIU8xGGR1z/FWVeqrpuVsA88cZqzNl594YFe4NZ+oqVACoQCcsOua1huapNGZOTJqVjE54aVRg969Jt2UEBQMgCvH5Zxa69p7FyV8zPzdq9RguVHzBlGTnrV4mDSic8nzNo1iBvztwR3pvIdiByeBVNbsqxJ6fWh7o7Sc49q5LEcrLm7bkEAD+dSRYX6msm0uJyGM6rv3HGD27Vfjk3HDDI9CelDQpJotAgqQx24PFG5VGeMehqBRl8+nNSsgbgnAIyOKaM3YecNyG49BTC+7cORjpUb5RMKeB61KpZl5xmqJ2K80pjwTyW4xUKu8jYcHGfwNWZkXdlRk9val4IUbR0wapFcysMDbFPHU80rMu3c6g9wKa8ZxwcHNJty+WJJHHSrI0B3BOB1HJwe1Mhbau3BIJyeKHh3OSH69sVCFEbuyvknqM07gkrFxnJdSCw2jjHemKn7zzUZlYDFVmLEZ8xuueKPMbALZ3DtnigXJbYvRvtYcg/rmnhVDEAEg8nPQVQSVNuDkrng06aYLtEZIywycZyPSrTMpU2W3wAMHA7f8A16jkPyknjjpjrTJJVEeCBj2qobrBwAePbjFUtSeVlkv8xUfe757VVnmB6DPbPaphOjg5HOM1SlJCkgbVJ4ppagiGd8DnOPX0rG1CRFuMFZDxWy2HHPbkVzfiC4jhvVWRiG8sH7wHrVoFozvUwDlRmrAk/d/Q9MVShfLKWO088etWTgkMCfQ81zlta2ZaWQHgctjPHSnqx2jZ8xHUGoLclSRxtOMD0qdWG8gdqliaJAeADx3x6U0PKJVUR7kwdz5+76fWkY5yQcLTxu3BgMDHSgVhx+6MZz1+lKV3dMjmkibcDuGPakdscflRcVmOwFB5zuP600kqSDnn1pQwcZGaYjHeVbp2zUtlJDWRmB2j60o7I2RjsadKShyCOajfpxxigpO4584AxjB6DuKRWG8nnnoaPnK89e1SbPmByKkpDXCybFfjawbg45pJVUjd37Gh4gCCc7j0I7UqMVBEibvQjsaL30KStqitKWCheuP1pkbkkjIwOhNWZYlZecjJqFIFQHbxk8+9SbJpoRyc4XO7rjrUDpwVcnnkg1ZlUKhzwP5VVncsoXhh6UrjjqUrm33btwLDrgHFU0ihdAqHDA4K9xWpI0SW5bzCMdjWTMIZTvjJViOMcGqi+50QuySayjCgKjDI4IPIrB1VHtwQzZyO1XLi7ubaI7Ljcw6bwK5fVJrqR1luZHyTwW+7+FdNKCYe8t2cp4nkK3EciElkOQakHjfU1jVUS2BAxkqT/Ws/X5t8jYyPUVhk17dKjGcEpq55GIrSjUfKzr18e6upGfsx/wCAH/GrMfxE1EEeZb27fQEZrhs0hNU8HRf2UYfW6i6npNv8SnU4msQV77W5Fa9n8SdLYnz45oj/ALS5rx/dSFqzll1CXSw1jqi31PoCy8Z6Rdn93qFvn/aJU/rW3batBOMRzxOe2GBr5jJBPIFSQ3M0JzDNLGR02sRWEsqi/hkUscvtRPqATFsA5I96kWcKRk8d+OlfOtn4x16zwItRkZR/C4B/pW/p/wATtRiAF5bxzjuV+UmuaWWVY7WZrHF0pb6Ht3mqTkHrTRPjAPrXm1h8SNKnAFyZ7Zv9pMj866Cz8T6VdhfJ1CFjnjLY/DmuaWHqQ+KLNlKEtmmdTJdKFOM/QUsbIyg4JPvWG92H5hIYeqnOanhumx8xOfWosy3T00NKXHReh61C6bQBt5/vU0XK5+9261G11gluCPShE6iOrJux+lNXc/OcineYhPGSW6+lML7G+bp6ZqmWrsR1O0Yyozk89amQ/KCc8HoKiEglJyjjBxhhj8R7UfKGzk+9Mhjt5b7pHuKhZ8uwJO30pX252jHJqNnwx3BTVrQi1xdwQHaee/NRyybgCSce9NRgzEcfT1ps6AjDEgnp7UBZIinkGRhfm/SvOfiFemHW4k4H+jqf1au+kJCOqA7gMfNXkvxMkY+I1VsZW3Rf1NdeDhzVLMwxUuWndHvsbZ+fGV7VYjIKnByBgiq8IQYByCanhIIyR17V57NrlgEE8cEjNOTcZMk/L0qHJzkHj0pySJk4PapHYsRsoYqRk46VOrDaPQVUjPA5LHufSpH9DztPWglq7JXYdQeB2qOSQNINwwT05qDduCld27oc1DPIY5VJPyngg1JcYl7zCR1I7EetO3HcFI6/oaqQSAqO2eanDbsAjn1pXG42JwwJKkcjvTXxgmkkhcKrZ7ZBHekjbOGIz2PNMj0Fi6jBJHQDvTlOwdttOCZ3EgZHT3qOSRMYdwG9DUMuOo9Om4HcpPOacTuyyj8D0FQkqoyH4Pp3p5bkCMDnk88VJVipq0t5HZu2mQJcXZIVFc7VTPG4+oHXHepVZ1iUTFZJUUB3VcBmxyQOwJzUhbDHHPrTGZcEE5xzmm9rFLcrvKpU5YAE4wfWq00YwQuAR8wYHFWJQq5O7NVZuSCB06DNI2j5EE0hVSXCtxyTVLLDhivr0qxcbmBVV9+Kpu7YZWCjnkn1ppGyMzUlW4JDDg/lmud1Iv03FkAwAegrqbpRjClTjnHpWBqEalHG4qe5rqouzKlqjzjVlIkbPc1kmtjWhtnIBJ+tYzdTX0VHWJ8/itJCZpCaCaStjjbFzSE0lIaCbi5puaDSZpibFzS5puaM0CuOyaOKZRmgLl611G8tiDb3dxHj+7IQK2rXxnrVvgG5EyjtIM1zGad2rOVKEviRpGrOPws722+I04UreWSt23RPg/rW5Y+O9LuNqyySwNjnzBx+deSE0mawlgqUtlY3jjqsd9T3+z1i2uowbadJAe6MCa0Eu0GC5J7V85Ru0b742KMOhU4NbVl4q1mzUCO8Z19JAG/nXLPLX9lnTHMIv4lY93a6XomTSeZxkfnXklp8Q76PAubWCX1Zcqa17X4g2crATwyw+/UVzvBVY9DaOIpS2l956G0w6kg+4qjdMXc4/wAKw7bxNZ3i4t54yfQNz+VWP7RilOI8eb6GsvZyi9UdMEnqjUjmIGed31pz3BJwcgY781npMWYZzmnPLt55pK9xyposGbOcPk464xXkHxAl8zxTdjOdm1f0r1Bp3DAEArnqa8g8TzCfxBfSA5BkPNd2BX7xvyPPx65aa9T6ThO/HHHan79kg6c9KpwzqSo5B/Q1KxUcbjnrXluJ0Jal5JN6Hp9elIuDxkhu1VY3+UN04xT0K7go79BWbRdrF2B2Dc8k9qfcHCOykgnmq6FhJ/s/zp5fDYJyT0xSZNtSu8u0A4+XqaHKycSEKB0xT3UKu3IOaq3AXacn51PXvSN1Z7F+IFI1II3Y696l8xXkzna3t0qkku3aATgiiRwuBjjPB96CeU0PtB80Kz8Acimo+GBU4HQEiqERdsuQVmHfPX3+lWYklEMe5iRnIGcjPehsXIkXnI4IfPXgGqsjBsKycn0P+eKmhYEjeMgHmm3UIUMy5yRzUPUcdHYrRGRJGQgOnbnn3FPjk80kJlfY8VWU58xATgHuOlTq0SxqoBD478fjmlY2kiyRsIyOg5JpyqMZwMH1qvGzF8MCB3JqxJjAGDwOoqbGb0IZIwpIYcHrVC7dYwNob+dXWztIYEDpn0qjOu47kPzDoT3oRpDzKnnkErgc9T2qGZ1UHepYfTikuNyONzfKTxSojZzuLDrz2q0jZ2WpmTuhb90hLf7XGaytU4Ung5HSty5hYDcynJP5Vz2ppJvbgbeg5rop6sdzgtfiJdm/KudkHNdZrg+fB54rl5lwxHpXv4d+6jxcZG8mVzSUpptdR5rCkNBpDTJA0lBooJCiiigAoq9pGlXmr3QgsIWlcnkgcD6mvT/D/wAL47cLNrMgmfGfKX7o+tZzqxhuylBs8qt7SWddyodnrSSRMhIYV7Trug2qWu2GFY1XoqivLNeg8uYjbjFTCrzs05EkYTdaQ06SmVsYsXNFJRQIWjNJSUBccDg5BINXrTVr60YNBcyDHYnIqhSUmk9yozcdYux1dn421GE/v0imHrt2mtu28c2kg/fxyRt9NwrzqkrCWFpS6HRHG1Y9b+p6vb+ILK6ZClxGx3A4J2/zrzC/fzL64cc7pGP61XzRTpUFSbaYq+KdaKTVrH0iZCp4TJyKuK6ttyOe/vWUjFiFLblHcdPzrQV9qqeigZ59K+fZ7LRagDICjOXPJHGOPSpI15BIwBUEDnduDZXOCD2q0rgA5znmoYth5Yo23qO9Jj5geg6VH5oAB+8G4yKeSRycE+/9am1wTaHux52AFvaq753M3Vj+lPZwpIHQntUeN6H1HHvSsXFipskX0I6/WrMQBJOMg9RVWNSZdo5ZhjH071NEwLDB6DHNJsqxbgA2ho+cHFSlMgqcjuMdqhRCVI3Bc88d6fv6E8jOKgllonGzIP4U9ZFbIA5HXjOagVgF+UHBPr0pQCMMueO1DRFiCSENuOMY9O4qMQBlB+8Oin0q4CCwJHB7elSkAAFVG2lymntGipEzeXhhjHrT3l4AAyRxxSXCmUbUJR+O3amKdoO7kjjgVNgunqNdzkksMniqs7gq2FXHpViUFdyqAWXBHHIqmS4O1sZApGsUtyqEVUIbsfzFVC3ll+oXnArRftuAYHoBVGZ1T7yZz6Griap3KtySkeRkk88nisW/zJlsbRjOa0b6RiAcAL35rPunABBJyRwDXRAdrHIaxEoEmSCfbtXH3akOfSu91KDhzgZNcXqaEPXs4WfQ87Fw6mW1MNSN1qMjmvQR40kJSUppKZmIaKKs6fZXOoXSW9lE00z9FUUN21YWuQIpdgqAsxOAAMk16H4K+G9zqrJcatvt7fORHj5mH9K6vwT4HtdD23WpMk12Rxn7qfSvQINRsIm2vdRBh2LVw1sS9oGqhbcboegWOj2yw2NusaDuByfrWjLGCDuGaE1G1cApMjD1BqnfataQKWeaNR15NcOrYaszdVsw6uAM5rzDxbo8ah3OAo55rq9f8faRZh1WdZpP7qc15L4q8VXOtylQPLt88KOp+tdlCnPcbkktTBvCnnMI+VB61XpaK9BaHO3d3EopKKBC0UlLQAUUlFAC9qKSloASiiigD6IhIUkBhtqVJVdNsn3c/nWeQ2VwSR1q3EwlhBUYXPT0r5lo+mt1NKJsIMEY9jyal8xGl2sW5HWqkCfMRnOOpNPt23A4GWU4Gah2BIvIqqqomNo6YpZgfk+X5ccnPNNtt24jB3dqlfDLw20jqDSsZvRkKBSBjcc/xHqBQmSxAOT6ntUmAi9OD6fz+tQRzlrjZGNuAD9fr70maRV9h2QZsf8ALQj88VZEibVMjAZPOf0FRSuqneyjcSF6VOURzl1R42G3awyKgbegtnJI8jsY3SMgBQ4w5POSR2FXEGVBGM896rSuY2KgMTj+GpLU5yCOCM5NKxD2uWYzsxn6GnHAbkD0FQyE7AckqvX2oV8EMcnp+FIVupJkqxAU4zkZp2/eMowBHUUwScdSAe9DqrAFZCrDr6GkHqIzELudifWoi7LIFz17Gp0ICnbtz24qIhVABOT6E5NIasMkbYD83zZ6VWyGBBHPXIp8qgliOW6j61DI5Z1IHA4OKRohswDJ1GM81lyxZ5TlSec1oOynnIGKpSlipERAGOMDFWjSDaMy4cEnByAcc1RukLAkjjHUnpV+aEDcXAPGPrVW6XCgbcY461tE1uc9eI205IrlNVjDA4BJz6V2V4xww2j2Nc9qERdiOlehQlZnPWjzI46ZCrEGoSK09QgKsegxWcwxXrQldHiVoWZGaaaeaaa0OVomsLOe/vIrW1QvLIdoFes6bHpvgfSS8iq+oMPnbqSfQe1cL4T1IaMss6RB7mQbQxH3R7VW1vUJ9QZ5p2JJ6c9K5qidSXL0N4R5Vcva3401PUZW2ztDF2VKwG1G5Z9xnkLepaqZBpCK2jTjHZGLnI2YPEuq28eyK7dVqldarfXeftF1K4PbdVKkzTUYroS5Nik96Q0UVRIlJS0UCCkopaACigUlABRRRTsAUtJRQAUUUUAe62t/HNxDIGGdoJUjmrkTgttI2Few5Boor52rBRdkfS05c25bM38Xf+dWLdgBx1+9RRWMi+hfWUY3DBGPSkLEtuBxnkUUVJlbUashKYbI9CO9RJkzEr9wjPPXNFFQ2ax2LUUbR7sENu6k9TVkp5alSTtPTnpRRSWpm2LOBLEDyCo69TVdbnG0KxXb1A9KKKRcFfQvk8DBzmhJsnDHuMcUUUpKxEFdMjvZCsJAABP61mWYmSdj5pkXhhu7e1FFK5vT0gzZMnyb8HJ/hqBwBIzAYbHJ6iiilcxWjIyWxl9pK9faodw5eQnJ5yPTtRRRbqaLUhkjPmYUcHoaqvFtLFlz3xmiinsVF3KJhc3Mk7TEowAWLHCnuc1VvFLKQhBI9RRRWsWWYk6ttbdyfSse+CLC0jcAUUV20tWjOo/dOO1K6E0hCLhazzRRXtQSSsjw6sm5airC8h+X+dXbTSpppQuBuPbNFFRUqNbDhTi7NnRR+Fr0KrDy8HtmqjaTcHIKocZ4zRRXGq0mb8qLun+G47uBnaUIQOm2svVtDjsmAZsg9MUUVpCcua1yJxVjKeyT+FjVaS3CjOaKK6oyZg4R7EJTFNIoorU5mrCEUhoooJYUlFFAgooopoAooooAKKKKACiiikB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with graft-versus-host disease after bone marrow transplantation with cutaneous manifestations similar to those observed in localized scleroderma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_30_17903=[""].join("\n");
var outline_f17_30_17903=null;
